Board of Pharmacy
BACKGROUND INFORMATION AND OVERVIEW
OF THE CURRENT REGULATORY PROGRAM
As of June 30, 2026

Section 1 – Background and Description of the Board and Regulated Profession

Established in 1891, the California State Board of Pharmacy (Board) initially registered 1,063 pharmacists and 369 pharmacist assistants in its first six years. Since then, both the Board and the professionals and businesses it regulates have experienced significant growth. Despite this expansion, consumer protection continues to remain the Board's primary focus as called for in its statutory mandate.

Today, the Board oversees 48 distinct license types, including seven individual temporary licenses issued to military spouses and partners. Its licensee population includes more than 50,400 pharmacists, 1,300 advanced practice pharmacists, 4,400 intern pharmacists, and 65,600 pharmacy technicians. The Board's regulatory authority is both broad and complex, extending across a wide spectrum of operations ranging from large institutional settings to small, independently operated facilities. Its jurisdiction includes the oversight of facilities nationwide, such as conducting mandatory inspections of nonresident sterile compounding pharmacies and outsourcing facilities that ship products into California. In addition, the Board conducts on-site inspections of automated drug delivery system locations where prescription medications are stored.

The Board comprises 13 members: seven pharmacists and six public representatives. The Senate Rules Committee and the Speaker of the Assembly each appoint one public member. The other 11 members are appointed by the Governor.

- Seung Oh, President, Licensee Member
- Jessica "Jessi" Crowley, Vice President, Licensee Member
- Renee Armendariz Barker, Treasure, Licensee Member
- Jeanette Dong, Public Member
- Jeff Hughes, Public Member
- Kartikeya "KK" Jha, Licensee Member
- Claudia L. Mercado, Public Member
- Jason Newell, Public Member
- Ricardo Sanchez, Public Member
- Satinder Sandhu, Licensee Member
- Maria Serpa, Licensee Member
- Nicole Thibeau, Licensee Member
- Vacant, Public Member

DRAFT

Individual License Types Issued by the Board

Provided are the license types issued by the Board including the statutory authority for each and a brief description of the respective roles.

Personal License Type	Authority	Definition
Advanced Pharmacist Practitioner (APH)	4016.5 4210	A licensee authorized to practice advanced practice pharmacy.
Designated Paramedic (DPM)	4119.01 4202.5	A licensee who may transport dangerous drugs and devices and may stock emergency medical services automated drug delivery systems.
Designated Representative – Wholesaler (EXC)	4022.5 4053	A licensee who is responsible for distribution functions performed by a wholesaler or veterinary food-animal drug retailer.
Designated Representative-3PL (DRL)	4022.7 4053.1	A licensee who is responsible for distribution functions performed by a third-party logistics provider.
Designated Representative-Reverse Distributor (DRR)	4022.6 4053.2	A licensee who is responsible for supervision over a licensed wholesaler that acts as a reverse distributor.
Intern Pharmacist (INT)	4030 4208	A licensee who is training to become a pharmacist and gaining the experience necessary for licensure while under the supervision of a pharmacist.
Pharmacist (RPH)	4036 4200 4036	A licensee who has qualified to practice pharmacy on the basis of education, training and minimum competency as demonstrated by passing national and state licensure examinations.
Pharmacy Technician (TCH)	4038 4202	A licensee who assists a pharmacist by performing nondiscretionary tasks related to the practice of pharmacy under the direct supervision of a pharmacist.

DRAFT

Business License Types Located Within California

Business License Type	Authority	Definition
Automated Drug Delivery System (ADD)	4017.3 4105.5 4119.1 4119.01 4187.5	A mechanical system that performs operations or activities, other than compounding or administration, relative to storage, dispensing, or distribution of drugs. ADDS includes "automated unit dose systems" (AUDS) for unit dose administration and "automated patient dispensing systems" (APDS) for dispensing drugs directly to patients.
Automated Drug Delivery Services-Emergency Medical Services (ADE)	4034.5 4119.01	An automated drug delivery system that stores and distributes drugs for the sole purpose of restocking a secured emergency pharmaceutical supplies container that is used by an emergency medical services agency.
Automated Patient Dispensing System - 340B Clinic "covered entity" (ADC)	4119.11	A pharmacy located in the state may provide pharmacy services to the patients of a "covered entity," as defined in Section 256b of Title 42 of the United States Code, through the use of an automated patient dispensing system located on the premises of the covered entity or on the premises of medical professional practices under contract to provide medical services to covered entity patients, which need not be the same location as the pharmacy. An "automated patient dispensing system" (APDS) is an ADDS for storage and dispensing of prescribed drugs directly to patients pursuant to prior authorization by a pharmacist.
Centralized Hospital Packaging (CHP/CHE)	4128 4128.2	A specialty license that allows a hospital to prepare unit-dose medications for its inpatients as well as inpatients of hospitals under common ownership.
Clinic (CLN/CLE) • **Community** • **Surgical**	4180 4190	A community, nonprofit, ambulatory surgery center, or other specific facility that purchases drugs at wholesale prices for administration or dispensing from a common drug supply to patients registered for care at the clinic.

Business License Type	Authority	Definition
Correctional Clinic (CLE)	4187 4187.1	A primary care clinic operated by the Department of Corrections and Rehabilitation to provide health care to eligible patients.
Exempt Hospital (Drug Room)(DRM/DRE)	4056	A pharmacy located within a hospital that contains 100 beds or fewer and does not employ a full-time pharmacist.
Hospital Pharmacy (HSP/HPE)	4029 4110	A pharmacy located within a licensed hospital, institution, or establishment to which persons may be admitted for overnight stay.
Hospital Satellite Compounding Pharmacy (SCP/SCE)	4127.15	Hospital satellite compounding pharmacy compounds sterile drug products for administration only to registered hospital patients who are on the premises of the same physical plant in which the hospital satellite compounding pharmacy is located.
Hypodermic Needle and Syringe (HYP)	4205	An entity authorized to sell and furnish hypodermic needles and syringes for animal use, or mercury containing fever monitors that is not otherwise licensed by the Board.
Licensed Correctional Pharmacy (LCF)	4021.5 4110	A pharmacy located within a correctional facility to provide pharmaceutical care to inmates and provide drugs to correctional clinics.
Outsourcing Facility	4034 4129	A facility engaged in the compounding of sterile and nonsterile drugs.
Pharmacy **•Community** **•Hospital Outpatient** **•Closed Door**	4037 4110	The premises where controlled substances and prescription drugs or devices are stored, possessed, prepared, manufactured, derived, repackaged, furnished, sold, or dispensed at retail to patients.
Remote Dispensing Site Pharmacy (PHR)	4044.3 4130	A pharmacy that is exclusively overseen and operated by a supervising pharmacy and staffed by one or more qualified pharmacy technicians.
Sterile Compounding Pharmacy (LSC/LSE)	4127 4127.1	A specialty license issued to a pharmacy that compounds sterile drug products.

Business License Type	Authority	Definition
Surplus Medication Collection and Distribution Intermediary (SME)	4046 4169.5	An entity that facilitates the donation of medications or transfer of medications between participating entities to be dispensed to indigent patients.
Third-Party Logistics Provider (TPL)	4045 4160 4162	An entity that provides or coordinates warehousing or other logistics services for dangerous drugs or devices on behalf of a manufacturer, wholesaler or dispenser but does not take ownership of the products or have responsibility to direct the sale or disposition of these items.
Veterinary Food-Animal Drug Retailer (VET)	4041 4196	A specialty license that allows a wholesaler that distributes veterinary drugs for food-producing animals to directly label and provide these drugs when prescribed by a veterinarian.
Wholesaler (WLS/WLE)	4043 4160 4162	An entity who sells for resale, or negotiates for distribution, or takes possession, of any dangerous drug or device. Additionally, dialysis patients may receive dialysis prescription drugs and dialysis medical devices from a wholesaler.

Business License Types Located Outside California

Business License Type	Authority	Definition
Nonresident Outsourcing Facility (NSF)	4034 4129.2	An out-of-state facility engaged in the compounding of sterile and nonsterile drugs that ships products into California.
Nonresident Pharmacy (NRP)	4037 4112	A pharmacy located outside of California that ships, mails or delivers, in any manner, controlled substances or prescription drugs or devices to patients in California.
Nonresident Sterile Compounding Pharmacy (NSC)	4127.2	A specialty license issued to a pharmacy outside of California that compounds sterile drug products and ships them to California patients and practitioners.
Nonresident Third-Party Logistics Provider (NPL)	4045 4161 4162.5	An entity located outside of California that provides or coordinates warehousing or other logistics services on behalf of a manufacturer, wholesaler or dispenser and ships those products into California.

Business License Type	Authority	Definition
Nonresident Wholesaler (OSD)	4043 4161 4162.5	An entity located outside of California that acts as a wholesale merchant, broker, jobber, customs broker, reverse distributor, who sells for resale, or negotiates for distribution, or takes possession, of any dangerous drug or device and ships them to practitioners or licensed entities in California.

DRAFT

Responsible Persons of a Licensed Facility

In addition, the Board recognizes and approves individuals who are responsible for the overall operations and regulatory compliance by licensed businesses; however, a special license is not required.

Responsible Persons	Authority	Definition
Designated Representative-in-Charge (DRIC)	4022.5 4053	A licensed designated representative or a pharmacist responsible for ensuring a wholesaler's or veterinary food-animal drug retailer's compliance with all state and federal laws and regulations.
Pharmacist-in-Charge (PIC)	4036.5 4101 4113	A licensed pharmacist responsible for ensuring a pharmacy's operations and compliance with all state and federal laws and regulations.
Responsible Manager (RMG)	4022.7(b) 4160	A licensed designated representative-3PL responsible for ensuring a third-party logistics provider's compliance with state and federal laws and regulations.

Board Committees and their Functions

The Board performs much of its work in committees. These committees develop and recommend policies that advance mission-related goals in the Board's strategic plan. The Board discusses, modifies and acts upon committee recommendations at public meetings. In addition to standing committees, the Board has temporary task force or ad hoc committees and one specialized standing committee.

The Board's strategic plan serves at the framework for managing, planning, and evaluating its regulatory jurisdiction and operations. This plan is updated annually and undergoes a comprehensive reassessment every five years to ensure that it remains aligned with the Board's evolving priorities and the Board's consumer protection mandate. The current plan was established in 2022.

Committee Membership

With the exception of the Organizational Development Committee, each of the Board's committees is composed of both licensee and public members. The Board President appoints the chairperson and vice-chairperson for each committee. The chairperson is responsible for coordinating the committee's activities, leading meetings, providing progress reports to the full Board, and ensuring alignment with the Board's strategic priorities. Agendas and meeting materials are posted online before meetings.

Committees typically meet either quarterly or semi-annually, and the public is encouraged to attend and offer comments. The chairperson presents relevant issues for discussion, and after thorough review at one or more meetings, the committee may vote of policy recommendations to be brought before the full Board. These recommendations do not

DRAFT

become Board policy until they are publicly noticed, discussed and formally voted upon by the full Board during a public meeting.

Committee meetings serve as an important forum for members, staff, and the public to discuss and resolve issues related to the Board's jurisdiction. The process promotes public involvement and supports the Board in evaluating policy changes, as well as in achieving its strategic goals.

Licensing Committee

This committee oversees the professional qualifications of licensees entering the practice of pharmacy, establishes minimum standards for Board-licensed facilities, and ensures appropriate practice standards.

Current members:

- Seung Oh, Chair, Licensee Member
- Satinder Sandhu, Vice-Chair, Licensee Member
- Jessica Crowley, Licensee Member
- Kartikeya Jha, Licensee Member
- Claudia Mercado, Public Member

Enforcement and Compounding Committee

This committee exercises oversight of all drug distribution and dispensing activities – including drug compounding – and enforcement of state and federal pharmacy laws. This committee typically convenes four times a year.

Current members:

- Renee Armendariz Barker, Chair, Licensee Member
- Maria Serpa, Vice-Chair, Licensee Member
- R. Jeffrey Hughes, Public Member
- Seung Oh, Licensee Member
- Ricardo Sanchez, Public Member
- Nicole Thibeau, Licensee Member

Communication and Public Education Committee

This committee is responsible for promoting public awareness, outreach and information for consumers, including the importance of discussing medications with their pharmacists, encouraging patients to comply with their prescription treatment regimens, and fostering enhanced understanding about drug therapy and overall health. The committee also ensures development of educational materials for licensees related to new laws, Board policies, and emerging issues. This committee typically convenes twice a year.

Current members:

- Nicole Thibeau Chair, Licensee Member

DRAFT

- Jason Newell, Public Member
- Renee Barker, Licensee Member
- Claudia Mercado, Public Member
- Kartikeya Jha, Licensee Member

Legislation and Regulation Committee
This committee advocates legislation and promulgates regulations that advance the Board's vision and mission.

Current members:
- Jessica Crowley, Chair, Licensee Member
- Nicole Thibeau, Vice-Chair, Licensee Member
- Jeanette Dong, Public Member
- Kartikeya Jha, Licensee Member
- Maria Serpa, Licensee Member

Organizational Development Committee
This committee is composed of the Board president and vice president and does not convene publicly. The committee is responsible for strategic planning, budget management, and staff development activities. During quarterly Board meetings the committee reports on the Board's expenditures, revenue, and fund condition, member attendance, member mail vote participation and future meeting dates.

Current members:
- Seung Oh, President, Licensee Member
- Jessica Crowley, Vice President, Licensee Member

Disciplinary Petition Committee
This committee convenes with an administrative law judge to consider petitions for reinstatement of a license or to consider modification of a penalty consistent with the provisions of BPC section 4039. This committee typically convenes four times a year.

Current members:
All Board members. Board members are rotated through the committee annually, with each member assigned on average to two of the four meeting dates.

Competency Committee
The Competency Committee is a special standing committee under the auspices of the Licensing Committee. Along with a contracted psychometrician, this committee is responsible for developing and scoring the Board's pharmacist licensure examination, the California Practice Standards and Jurisprudence Examination for Pharmacists (CPJE). Membership on this committee is highly selective and represents the breadth of California pharmacy practice. The work is professionally challenging and time-consuming; members

DRAFT

attend nine meetings two-day meetings annually. These meetings are not public, as they handle confidential licensure examination content and are explicitly exempt from the Bagley-Keene Open Meetings Act.

Pharmacy Technician Advisory Committee (PTAC)

This committee was established pursuant to Assembly Bill 1503 (Berman, Chapter 196, Statutes of 2025). Business and Professions Section 4001.5 authorizes the Board to establish a Pharmacy Technician Advisory Committee to advise and make recommendations to the Board on matters relating to pharmacy technicians. The committee shall consist of four licensed pharmacy technicians representing a range of practice settings; two licensed pharmacists, one of whom shall be a member of the Board; and one public member. All technician appointees shall hold an active technician license and shall be in good standing. The Board is working toward standing up this committee and anticipates the appointments to be completed by the end of calendar year 2026.

Meeting Quorums

Business and Professions Code section 4002 requires the presence of seven Board members to take action at meetings and constitute a quorum. To minimize scheduling conflicts and secure meeting space, the Board generally schedules meetings for the coming year in April or July. Typically, the Board meets eight times annually. Items submitted by committees are considered at quarterly meetings, while the other meetings focus on petitions for reinstatement of licensure or early termination/other reduction in penalty. The Board occasionally schedules additional meetings to address emergent issues.

Fiscal Year	Number of Board Meetings	Board Meeting Days	Committee Meetings
FY 2024/25	10	15	17
FY 2025/26	6	10	14
FY 2026/27			
FY 2027/28			
Total	16	25	31

DRAFT

Board member attendance is reported quarterly. Board and Committee Member Roster to be provided as part of the final report. Outcomes of the Medication Error Reduction and Workforce and Standard of Care Ad Hoc Committees will also be highlighted in final report. A chart detailing the licensing programs, authority and brief description will also be provided.

Table 1a. Attendance			
Licensee Member: Seung Oh			
Date Appointed: 02/24/2020	Reappointed: 03/19/2024		
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Enforcement and Compounding Committee	07/17/2024	Webex, Sacramento	Y
Licensing Committee Meetings	07/18/2024	Webex, Sacramento	Y
Board Meeting	07/31/2024	Webex, Sacramento	Y
Board Meeting	08/01/2024	Webex, Sacramento	Y
Licensing Committee Meetings	09/04/2024	Webex, Sacramento	Y
Board Meeting	09/12/2024	Webex, Sacramento	Y
Enforcement and Compounding Committee	10/16/2024	Webex, Sacramento	Y
Licensing Committee Meetings	10/17/2024	Webex, Sacramento	Y
Board Meeting	11/06/2024	Webex, San Diego	Y
Board Meeting	11/07/2024	Webex, San Diego	Y
Board Meeting	12/04/2024	Webex, Sacramento	Y
Disciplinary Petition Committee	12/18/2024	Webex, Sacramento	Y
Board Meeting	01/08/2025	Webex, Sacramento	Y
Board Meeting	02/05/2025	Webex, Sacramento	Y
Board Meeting	02/06/2025	Webex, Sacramento	Y
Board Meeting	03/06/2025	Webex, Sacramento	Y
Board Meeting	03/26/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	03/27/2025	Webex, Sacramento	Y
Board Meeting	04/09/2025	Webex, Sacramento	Y
Board Meeting	04/10/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	06/11/2025	Webex, Sacramento	Y
Licensing Committee Meetings	06/12/2025	Webex, Sacramento	Y
Board Meeting	06/19/2025	Webex, Sacramento	Y
Board Meeting	06/20/2025	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Licensee Member: Seung Oh			
Date Appointed: 02/24/2020	Reappointed: 03/19/2024		
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2025/26			
Board Meeting	09/11/2025	Webex, Sacramento	Y
Licensing Committee Meetings	10/15/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	10/16/2025	Webex, Sacramento	Y
Board Meeting	11/05/2025	Webex, Garden Grove	Y
Board Meeting	11/06/2025	Webex, Garden Grove	Y
Enforcement and Compounding Committee	01/07/2026	Webex, Sacramento	Y
Licensing Committee Meetings	01/08/2026	Webex, Sacramento	Y
Board Meeting	01/26/2026	Webex, Sacramento	Y
Board Meeting	01/27/2026	Webex, Sacramento	Y
Board Meeting	03/18/2026	Webex, Sacramento	Y
Licensing Committee Meetings	04/15/2026	Webex, Sacramento	Y
Enforcement and Compounding Committee	04/16/2026	Webex, Sacramento	Y
Board Meeting	04/29/2026	Webex, Sacramento	Y
Board Meeting	04/30/2026	Webex, Sacramento	Y
Enforcement and Compounding Committee	06/10/2026	Webex, Sacramento	Y
Licensing Committee Meetings	06/11/2026	Webex, Sacramento	Y
Board Meeting	06/24/2026	Webex, Sacramento	Y
Board Meeting	06/25/2026	Webex, Sacramento	Y

Table 1a. Attendance			
Licensee Member: Jessica Crowley			
Date Appointed: 5/19/2022	Reappointment: 4/29/2026		
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Legislation and Regulation Committee	07/17/2024	Webex, Sacramento	Y
Licensing Committee Meetings	07/18/2024	Webex, Sacramento	Y
Board Meeting	07/31/2024	Webex, Sacramento	N

DRAFT

Table 1a. Attendance			
Licensee Member: Jessica Crowley			
Date Appointed: 5/19/2022	Reappointment: 4/29/2026		
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Board Meeting	08/01/2024	Webex, Sacramento	N
Disciplinary Petition Committee	08/23/2024	Webex, Sacramento	Y
Licensing Committee Meetings	09/04/2024	Webex, Sacramento	Y
Board Meeting	09/12/2024	Webex, Sacramento	Y
Licensing Committee Meetings	10/17/2024	Webex, Sacramento	Y
Board Meeting	11/06/2024	Webex, San Diego	Y
Board Meeting	11/07/2024	Webex, San Diego	Y
Board Meeting	12/04/2024	Webex, Sacramento	Y
Board Meeting	01/08/2025	Webex, Sacramento	Y
Board Meeting	02/05/2025	Webex, Sacramento	Y
Board Meeting	02/06/2025	Webex, Sacramento	Y
Board Meeting	03/06/2025	Webex, Sacramento	N
Board Meeting	03/26/2025	Webex, Sacramento	N
Board Meeting	04/09/2025	Webex, Sacramento	Y
Legislation and Regulation Committee	04/09/2025	Webex, Sacramento	Y
Board Meeting	04/10/2025	Webex, Sacramento	Y
Disciplinary Petition Committee	05/21/2025	Webex, Sacramento	Y
Legislation and Regulation Committee	06/11/2025	Webex, Sacramento	Y
Licensing Committee Meetings	06/12/2025	Webex, Sacramento	Y
Board Meeting	06/19/2025	Webex, Sacramento	N
Board Meeting	06/20/2025	Webex, Sacramento	N
Fiscal Year 2025/26			
Board Meeting	09/11/2025	Webex, Sacramento	N
Licensing Committee Meetings	10/15/2025	Webex, Sacramento	N
Board Meeting	11/05/2025	Webex, Garden Grove	Y
Board Meeting	11/06/2025	Webex, Garden Grove	Y
Licensing Committee Meetings	01/08/2026	Webex, Sacramento	N
Board Meeting	01/26/2026	Webex, Sacramento	N
Board Meeting	01/27/2026	Webex, Sacramento	N
Board Meeting	03/18/2026	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Licensee Member: Jessica Crowley			
Date Appointed: 5/19/2022	Reappointment: 4/29/2026		
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Licensing Committee Meetings	04/15/2026	Webex, Sacramento	Y
Board Meeting	04/29/2026	Webex, Sacramento	Y
Legislation and Regulation Committee	04/29/2026	Webex, Sacramento	Y
Board Meeting	04/30/2026	Webex, Sacramento	Y
Legislation and Regulation Committee	06/11/2026	Webex, Sacramento	Y
Licensing Committee Meetings	06/11/2026	Webex, Sacramento	Y
Board Meeting	06/24/2026	Webex, Sacramento	Y
Board Meeting	06/25/2026	Webex, Sacramento	Y

Table 1a. Attendance			
Licensee Member: Renee Barker			
Date Appointed: 6/24/2022	Date of Reappointment 4/25/2024		
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Enforcement and Compounding Committee	07/17/2024	Webex, Sacramento	Y
Communication and Public Education Committee	07/18/2024	Webex, Sacramento	Y
Licensing Committee Meetings	07/18/2024	Webex, Sacramento	Y
Board Meeting	07/31/2024	Webex, Sacramento	Y
Board Meeting	08/01/2024	Webex, Sacramento	N
Licensing Committee Meetings	09/04/2024	Webex, Sacramento	Y
Board Meeting	09/12/2024	Webex, Sacramento	Y
Enforcement and Compounding Committee	10/16/2024	Webex, Sacramento	Y
Licensing Committee Meetings	10/17/2024	Webex, Sacramento	Y
Board Meeting	11/06/2024	Webex, San Diego	Y
Board Meeting	11/07/2024	Webex, San Diego	Y
Board Meeting	12/04/2024	Webex, Sacramento	Y
Board Meeting	01/08/2025	Webex, Sacramento	Y
Board Meeting	02/05/2025	Webex, Sacramento	Y
Board Meeting	02/06/2025	Webex, Sacramento	Y
Board Meeting	03/06/2025	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Licensee Member: Renee Barker			
Date Appointed: 6/24/2022 Date of Reappointment 4/25/2024			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Disciplinary Petition Committee	03/12/2025	Webex, Sacramento	N
Board Meeting	03/26/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	03/27/2025	Webex, Sacramento	Y
Board Meeting	04/09/2025	Webex, Sacramento	Y
Board Meeting	04/10/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	06/11/2025	Webex, Sacramento	Y
Communication and Public Education Committee	06/12/2025	Webex, Sacramento	Y
Licensing Committee Meetings	06/12/2025	Webex, Sacramento	Y
Board Meeting	06/19/2025	Webex, Sacramento	Y
Board Meeting	06/20/2025	Webex, Sacramento	Y
Fiscal Year 2025/26			
Board Meeting	09/11/2025	Webex, Sacramento	N
Licensing Committee Meetings	10/15/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	10/16/2025	Webex, Sacramento	Y
Board Meeting	11/05/2025	Webex, Garden Grove	Y
Board Meeting	11/06/2025	Webex, Garden Grove	Y
Enforcement and Compounding Committee	01/07/2026	Webex, Sacramento	Y
Communication and Public Education Committee	01/08/2026	Webex, Sacramento	Y
Licensing Committee Meetings	01/08/2026	Webex, Sacramento	Y
Board Meeting	01/26/2026	Webex, Sacramento	Y
Board Meeting	01/27/2026	Webex, Sacramento	Y
Board Meeting	03/18/2026	Webex, Sacramento	Y
Licensing Committee Meetings	04/15/2026	Webex, Sacramento	Y
Enforcement and Compounding Committee	04/16/2026	Webex, Sacramento	Y
Board Meeting	04/29/2026	Webex, Sacramento	Y
Board Meeting	04/30/2026	Webex, Sacramento	Y
Disciplinary Petition Committee	05/19/2026	Webex, Sacramento	Y
Communication and Public Education Committee	06/10/2026	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Licensee Member: Renee Barker			
Date Appointed: 6/24/2022 Date of Reappointment 4/25/2024			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Enforcement and Compounding Committee	06/10/2026	Webex, Sacramento	Y
Licensing Committee Meetings	06/11/2026	Webex, Sacramento	Y
Board Meeting	06/24/2026	Webex, Sacramento	Y
Board Meeting	06/25/2026	Webex, Sacramento	Y

Table 1a. Attendance			
Public Member: Jeanette Dong			
Date Appointed: 7/19/2025			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2025/26			
Board Meeting	09/11/2025	Webex, Sacramento	N
Board Meeting	11/05/2025	Webex, Garden Grove	Y
Board Meeting	11/06/2025	Webex, Garden Grove	Y
Board Meeting	01/26/2026	Webex, Sacramento	Y
Board Meeting	01/27/2026	Webex, Sacramento	Y
Board Meeting	03/18/2026	Webex, Sacramento	N
Board Meeting	04/29/2026	Webex, Sacramento	Y
Board Meeting	04/30/2026	Webex, Sacramento	Y
Board Meeting	06/24/2026	Webex, Sacramento	N
Board Meeting	06/25/2026	Webex, Sacramento	N
Legislation and Regulation Committee	04/29/2026	Webex, Sacramento	Y
Legislation and Regulation Committee	06/11/2026	Webex, Sacramento	N

Table 1a. Attendance			
Public Member: Jeff Hughes			
Date Appointed: 03/19/2024			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Enforcement and Compounding Committee	07/17/2024	Webex, Sacramento	N
Board Meeting	07/31/2024	Webex, Sacramento	Y
Board Meeting	08/01/2024	Webex, Sacramento	Y
Board Meeting	09/12/2024	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Public Member: Jeff Hughes			
Date Appointed: 03/19/2024			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Enforcement and Compounding Committee	10/16/2024	Webex, Sacramento	Y
Board Meeting	11/06/2024	Webex, San Diego	Y
Board Meeting	11/07/2024	Webex, San Diego	Y
Board Meeting	12/04/2024	Webex, Sacramento	Y
Disciplinary Petition Committee	12/18/2024	Webex, Sacramento	N
Board Meeting	01/08/2025	Webex, Sacramento	Y
Board Meeting	02/05/2025	Webex, Sacramento	Y
Board Meeting	02/06/2025	Webex, Sacramento	Y
Board Meeting	03/06/2025	Webex, Sacramento	Y
Disciplinary Petition Committee	03/12/2025	Webex, Sacramento	Y
Board Meeting	03/26/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	03/27/2025	Webex, Sacramento	N
Board Meeting	04/09/2025	Webex, Sacramento	Y
Board Meeting	04/10/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	06/11/2025	Webex, Sacramento	N
Board Meeting	06/19/2025	Webex, Sacramento	Y
Board Meeting	06/20/2025	Webex, Sacramento	Y
Fiscal Year 2025/26			
Board Meeting	09/11/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	10/16/2025	Webex, Sacramento	Y
Board Meeting	11/05/2025	Webex, Garden Grove	N
Board Meeting	11/06/2025	Webex, Garden Grove	N
Enforcement and Compounding Committee	01/07/2026	Webex, Sacramento	Y
Board Meeting	01/26/2026	Webex, Sacramento	Y
Board Meeting	01/27/2026	Webex, Sacramento	Y
Board Meeting	03/18/2026	Webex, Sacramento	Y
Enforcement and Compounding Committee	04/16/2026	Webex, Sacramento	Y
Board Meeting	04/29/2026	Webex, Sacramento	N
Board Meeting	04/30/2026	Webex, Sacramento	N
Disciplinary Petition Committee	05/19/2026	Webex, Sacramento	N

DRAFT

Table 1a. Attendance			
Public Member: Jeff Hughes			
Date Appointed: 03/19/2024			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Enforcement and Compounding Committee	06/10/2026	Webex, Sacramento	N
Board Meeting	06/24/2026	Webex, Sacramento	Y
Board Meeting	06/25/2026	Webex, Sacramento	Y

Table 1a. Attendance			
Licensee Member: KK Jha			
Date Appointed: 09/09/2022 Reappointed: 5/22/2025			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2025/26			
Legislation and Regulation Committee	07/17/2024	Webex, Sacramento	Y
Communication and Public Education Committee	07/18/2024	Webex, Sacramento	Y
Board Meeting	07/31/2024	Webex, Sacramento	Y
Board Meeting	08/01/2024	Webex, Sacramento	Y
Disciplinary Petition Committee	08/23/2024	Webex, Sacramento	Y
Board Meeting	09/12/2024	Webex, Sacramento	Y
Board Meeting	11/06/2024	Webex, San Diego	Y
Board Meeting	11/07/2024	Webex, San Diego	Y
Board Meeting	12/04/2024	Webex, Sacramento	N
Board Meeting	01/08/2025	Webex, Sacramento	Y
Board Meeting	02/05/2025	Webex, Sacramento	Y
Board Meeting	02/06/2025	Webex, Sacramento	Y
Board Meeting	03/06/2025	Webex, Sacramento	Y
Board Meeting	03/26/2025	Webex, Sacramento	N
Board Meeting	04/09/2025	Webex, Sacramento	Y
Legislation and Regulation Committee	04/09/2025	Webex, Sacramento	N
Board Meeting	04/10/2025	Webex, Sacramento	N
Disciplinary Petition Committee	05/21/2025	Webex, Sacramento	N
Legislation and Regulation Committee	06/11/2025	Webex, Sacramento	Y
Board Meeting	06/19/2025	Webex, Sacramento	Y
Board Meeting	06/20/2025	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Licensee Member: KK Jha			
Date Appointed: 09/09/2022 Reappointed: 5/22/2025			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2025/26			
Board Meeting	09/11/2025	Webex, Sacramento	Y
Licensing Committee Meetings	10/15/2025	Webex, Sacramento	N
Board Meeting	11/05/2025	Webex, Garden Grove	Y
Board Meeting	11/06/2025	Webex, Garden Grove	Y
Disciplinary Petition Committee	12/03/2025	Webex, Sacramento	Y
Licensing Committee Meetings	01/08/2026	Webex, Sacramento	Y
Board Meeting	01/26/2026	Webex, Sacramento	Y
Board Meeting	01/27/2026	Webex, Sacramento	Y
Board Meeting	03/18/2026	Webex, Sacramento	Y
Licensing Committee Meetings	04/15/2026	Webex, Sacramento	N
Board Meeting	04/29/2026	Webex, Sacramento	Y
Legislation and Regulation Committee	04/29/2026	Webex, Sacramento	N
Board Meeting	04/30/2026	Webex, Sacramento	Y
Legislation and Regulation Committee	06/11/2026	Webex, Sacramento	Y
Licensing Committee Meetings	06/11/2026	Webex, Sacramento	Y
Board Meeting	06/24/2026	Webex, Sacramento	Y
Board Meeting	06/25/2026	Webex, Sacramento	Y

Table 1a. Attendance			
Public Member: Claudia Mercado			
Date Appointed: 04/9/2025			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Disciplinary Petition Committee	05/21/2025	Webex, Sacramento	N
Communication and Public Education Committee	06/12/2025	Webex, Sacramento	Y
Licensing Committee Meetings	06/12/2025	Webex, Sacramento	Y
Board Meeting	06/19/2025	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Public Member: Claudia Mercado			
Date Appointed: 04/9/2025			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Board Meeting	06/20/2025	Webex, Sacramento	Y
Fiscal Year 2025/26			
Board Meeting	09/11/2025	Webex, Sacramento	Y
Licensing Committee Meetings	10/15/2025	Webex, Sacramento	Y
Board Meeting	11/05/2025	Webex, Garden Grove	Y
Board Meeting	11/06/2025	Webex, Garden Grove	Y
Disciplinary Petition Committee	12/03/2025	Webex, Sacramento	Y
Communication and Public Education Committee	01/08/2026	Webex, Sacramento	Y
Licensing Committee Meetings	01/08/2026	Webex, Sacramento	Y
Board Meeting	01/26/2026	Webex, Sacramento	Y
Board Meeting	01/27/2026	Webex, Sacramento	Y
Board Meeting	03/18/2026	Webex, Sacramento	Y
Licensing Committee Meetings	04/15/2026	Webex, Sacramento	Y
Board Meeting	04/29/2026	Webex, Sacramento	Y
Board Meeting	04/30/2026	Webex, Sacramento	Y
Disciplinary Petition Committee	05/19/2026	Webex, Sacramento	Y
Communication and Public Education Committee	06/10/2026	Webex, Sacramento	Y
Licensing Committee Meetings	06/11/2026	Webex, Sacramento	Y
Board Meeting	06/24/2026	Webex, Sacramento	Y
Board Meeting	06/25/2026	Webex, Sacramento	Y

Table 1a. Attendance			
Public Member: Jason "Jay" Newell			
Date Appointed: 03/19/2024			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Communication and Public Education Committee	07/18/2024	Webex, Sacramento	Y
Board Meeting	07/31/2024	Webex, Sacramento	Y
Board Meeting	08/01/2024	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Public Member: Jason "Jay" Newell			
Date Appointed: 03/19/2024			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Disciplinary Petition Committee	08/23/2024	Webex, Sacramento	N
Board Meeting	09/12/2024	Webex, Sacramento	N
Board Meeting	11/06/2024	Webex, San Diego	Y
Board Meeting	11/07/2024	Webex, San Diego	Y
Board Meeting	12/04/2024	Webex, Sacramento	Y
Disciplinary Petition Committee	12/18/2024	Webex, Sacramento	Y
Board Meeting	01/08/2025	Webex, Sacramento	Y
Board Meeting	02/05/2025	Webex, Sacramento	Y
Board Meeting	02/06/2025	Webex, Sacramento	Y
Board Meeting	03/06/2025	Webex, Sacramento	Y
Board Meeting	03/26/2025	Webex, Sacramento	N
Board Meeting	04/09/2025	Webex, Sacramento	Y
Board Meeting	04/10/2025	Webex, Sacramento	Y
Disciplinary Petition Committee	05/21/2025	Webex, Sacramento	Y
Fiscal Year 2025/26			
Communication and Public Education Committee	06/12/2025	Webex, Sacramento	Y
Board Meeting	06/19/2025	Webex, Sacramento	Y
Board Meeting	06/20/2025	Webex, Sacramento	Y
Board Meeting	09/11/2025	Webex, Sacramento	Y
Board Meeting	11/05/2025	Webex, Garden Grove	Y
Board Meeting	11/06/2025	Webex, Garden Grove	Y
Disciplinary Petition Committee	12/03/2025	Webex, Sacramento	Y
Communication and Public Education Committee	01/08/2026	Webex, Sacramento	N
Board Meeting	01/26/2026	Webex, Sacramento	Y
Board Meeting	01/27/2026	Webex, Sacramento	Y
Board Meeting	03/18/2026	Webex, Sacramento	Y
Board Meeting	04/29/2026	Webex, Sacramento	Y
Board Meeting	04/30/2026	Webex, Sacramento	Y
Disciplinary Petition Committee	05/19/2026	Webex, Sacramento	Y
Communication and Public Education Committee	06/10/2026	Webex, Sacramento	Y
Board Meeting	06/24/2026	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Public Member: Jason "Jay" Newell			
Date Appointed: 03/19/2024			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Board Meeting	06/25/2026	Webex, Sacramento	Y

Table 1a. Attendance			
Public Member: Ricardo Sanchez			
Date Appointed: 03/14/2025			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Board Meeting	03/26/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	03/27/2025	Webex, Sacramento	Y
Board Meeting	04/09/2025	Webex, Sacramento	Y
Board Meeting	04/10/2025	Webex, Sacramento	Y
Disciplinary Petition Committee	05/21/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	06/11/2025	Webex, Sacramento	N
Communication and Public Education Committee	06/12/2025	Webex, Sacramento	N
Board Meeting	06/19/2025	Webex, Sacramento	Y
Board Meeting	06/20/2025	Webex, Sacramento	Y
Fiscal Year 2025/26			
Board Meeting	09/11/2025	Webex, Sacramento	Y
Enforcement and Compounding Committee	10/16/2025	Webex, Sacramento	Y
Board Meeting	11/05/2025	Webex, Garden Grove	Y
Board Meeting	11/06/2025	Webex, Garden Grove	Y
Enforcement and Compounding Committee	01/07/2026	Webex, Sacramento	Y
Communication and Public Education Committee	01/08/2026	Webex, Sacramento	Y
Board Meeting	01/26/2026	Webex, Sacramento	Y
Board Meeting	01/27/2026	Webex, Sacramento	Y
Board Meeting	03/18/2026	Webex, Sacramento	Y
Enforcement and Compounding Committee	04/16/2026	Webex, Sacramento	Y
Board Meeting	04/29/2026	Webex, Sacramento	Y
Board Meeting	04/30/2026	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Public Member: Ricardo Sanchez			
Date Appointed: 03/14/2025			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Communication and Public Education Committee	06/10/2026	Webex, Sacramento	Y
Enforcement and Compounding Committee	06/10/2026	Webex, Sacramento	Y
Board Meeting	06/24/2026	Webex, Sacramento	Y
Board Meeting	06/25/2026	Webex, Sacramento	Y

Table 1a. Attendance			
Public Member: Indira Cameron-Banks			
Date Appointed: 02/3/2022 Term Ended: 03/14/2025			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Enforcement and Compounding Committee	07/17/2024	Webex, Sacramento	N
Board Meeting	07/31/2024	Webex, Sacramento	Y
Board Meeting	08/01/2024	Webex, Sacramento	N
Board Meeting	09/12/2024	Webex, Sacramento	N
Enforcement and Compounding Committee	10/16/2024	Webex, Sacramento	N
Board Meeting	11/06/2024	Webex, San Diego	N
Board Meeting	11/07/2024	Webex, San Diego	N
Board Meeting	12/04/2024	Webex, Sacramento	N
Board Meeting	01/08/2025	Webex, Sacramento	N
Board Meeting	02/05/2025	Webex, Sacramento	N
Board Meeting	02/06/2025	Webex, Sacramento	N
Board Meeting	03/06/2025	Webex, Sacramento	N

Table 1a. Attendance			
Public Member: Trevor Chandler			
Date Appointed: 09/9/2022 Grace Term Ended: 06/1/2026			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Legislation and Regulation Committee	07/17/2024	Webex, Sacramento	N
Licensing Committee Meetings	07/18/2024	Webex, Sacramento	Y
Board Meeting	07/31/2024	Webex, Sacramento	N

DRAFT

Table 1a. Attendance			
Public Member: Trevor Chandler			
Date Appointed: 09/9/2022 Grace Term Ended: 06/1/2026			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Board Meeting	08/01/2024	Webex, Sacramento	N
Disciplinary Petition Committee	08/23/2024	Webex, Sacramento	Y
Licensing Committee Meetings	09/04/2024	Webex, Sacramento	Y
Board Meeting	09/12/2024	Webex, Sacramento	Y
Licensing Committee Meetings	10/17/2024	Webex, Sacramento	Y
Board Meeting	11/06/2024	Webex, San Diego	N
Board Meeting	11/07/2024	Webex, San Diego	N
Board Meeting	12/04/2024	Webex, Sacramento	Y
Board Meeting	01/08/2025	Webex, Sacramento	Y
Board Meeting	02/05/2025	Webex, Sacramento	Y
Board Meeting	02/06/2025	Webex, Sacramento	Y
Board Meeting	03/06/2025	Webex, Sacramento	Y
Disciplinary Petition Committee	03/12/2025	Webex, Sacramento	Y
Board Meeting	03/26/2025	Webex, Sacramento	Y
Board Meeting	04/09/2025	Webex, Sacramento	Y
Legislation and Regulation Committee	04/09/2025	Webex, Sacramento	Y
Board Meeting	04/10/2025	Webex, Sacramento	Y
Legislation and Regulation Committee	06/11/2025	Webex, Sacramento	Y
Licensing Committee Meetings	06/12/2025	Webex, Sacramento	Y
Board Meeting	06/19/2025	Webex, Sacramento	Y
Board Meeting	06/20/2025	Webex, Sacramento	Y
Fiscal Year 2025/26			
Board Meeting	09/11/2025	Webex, Sacramento	N
Licensing Committee Meetings	10/15/2025	Webex, Sacramento	Y
Board Meeting	11/05/2025	Webex, Garden Grove	Y
Board Meeting	11/06/2025	Webex, Garden Grove	Y
Licensing Committee Meetings	01/08/2026	Webex, Sacramento	N
Board Meeting	01/26/2026	Webex, Sacramento	N
Board Meeting	01/27/2026	Webex, Sacramento	N
Board Meeting	03/18/2026	Webex, Sacramento	Y

DRAFT

Table 1a. Attendance			
Public Member: Trevor Chandler			
Date Appointed: 09/9/2022 Grace Term Ended: 06/1/2026			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Licensing Committee Meetings	04/15/2026	Webex, Sacramento	N
Board Meeting	04/29/2026	Webex, Sacramento	N
Legislation and Regulation Committee	04/29/2026	Webex, Sacramento	N
Board Meeting	04/30/2026	Webex, Sacramento	N

Table 1a. Attendance			
Licensee Member: Satinder Sandhu			
Date Appointed: 03/19/2024 Reappointment date: 04/29/2026			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Licensing Committee Meetings	07/18/2024	Webex, Sacramento	Y
Board Meeting	07/31/2024	Webex, Sacramento	Y
Board Meeting	08/01/2024	Webex, Sacramento	Y
Disciplinary Petition Committee	08/23/2024	Webex, Sacramento	Y
Licensing Committee Meetings	09/04/2024	Webex, Sacramento	Y
Board Meeting	09/12/2024	Webex, Sacramento	Y
Licensing Committee Meetings	10/17/2024	Webex, Sacramento	Y
Board Meeting	11/06/2024	Webex, San Diego	Y
Board Meeting	11/07/2024	Webex, San Diego	Y
Board Meeting	12/04/2024	Webex, Sacramento	Y
Disciplinary Petition Committee	12/18/2024	Webex, Sacramento	Y
Board Meeting	01/08/2025	Webex, Sacramento	Y
Board Meeting	02/05/2025	Webex, Sacramento	Y
Board Meeting	02/06/2025	Webex, Sacramento	Y
Board Meeting	03/06/2025	Webex, Sacramento	Y
Disciplinary Petition Committee	03/12/2025	Webex, Sacramento	Y
Board Meeting	03/26/2025	Webex, Sacramento	Y
Board Meeting	04/09/2025	Webex, Sacramento	N
Board Meeting	04/10/2025	Webex, Sacramento	N

DRAFT

Table 1a. Attendance			
Licensee Member: Satinder Sandhu			
Date Appointed: 03/19/2024 Reappointment date: 04/29/2026			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Licensing Committee Meetings	06/12/2025	Webex, Sacramento	Y
Board Meeting	06/19/2025	Webex, Sacramento	Y
Board Meeting	06/20/2025	Webex, Sacramento	Y
Fiscal Year 2025/26			
Board Meeting	09/11/2025	Webex, Sacramento	Y
Licensing Committee Meetings	10/15/2025	Webex, Sacramento	Y
Board Meeting	11/05/2025	Webex, Garden Grove	Y
Board Meeting	11/06/2025	Webex, Garden Grove	Y
Disciplinary Petition Committee	12/03/2025	Webex, Sacramento	Y
Licensing Committee Meetings	01/08/2026	Webex, Sacramento	Y
Board Meeting	01/26/2026	Webex, Sacramento	Y
Board Meeting	01/27/2026	Webex, Sacramento	Y
Board Meeting	03/18/2026	Webex, Sacramento	Y
Licensing Committee Meetings	04/15/2026	Webex, Sacramento	Y
Board Meeting	04/29/2026	Webex, Sacramento	Y
Board Meeting	04/30/2026	Webex, Sacramento	Y
Licensing Committee Meetings	06/11/2026	Webex, Sacramento	Y
Board Meeting	06/24/2026	Webex, Sacramento	Y
Board Meeting	06/25/2026	Webex, Sacramento	Y

Table 1a. Attendance			
Public Member: Jason Weisz			
Date Appointed: 08/19/2020 Reappointed: 07/03/2024 Resigned: 01/29/2025			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Fiscal Year 2024/25			
Communication and Public Education Committee	01/22/2024	Webex, Sacramento	Y
Licensing Committee Meetings	07/18/2024	Webex, Sacramento	Y
Board Meeting	07/31/2024	Webex, Sacramento	N
Board Meeting	08/01/2024	Webex, Sacramento	N
Licensing Committee Meetings	09/04/2024	Webex, Sacramento	Y
Board Meeting	09/12/2024	Webex, Sacramento	N

DRAFT

Table 1a. Attendance			
Public Member: Jason Weisz			
Date Appointed: 08/19/2020 Reappointed: 07/03/2024 Resigned: 01/29/2025			
Meeting Type	**Meeting Date**	**Meeting Location**	**Attended?**
Licensing Committee Meetings	10/17/2024	Webex, Sacramento	N
Board Meeting	11/06/2024	Webex, San Diego	N
Board Meeting	11/07/2024	Webex, San Diego	Y
Board Meeting	12/04/2024	Webex, Sacramento	N
Board Meeting	01/08/2025	Webex, Sacramento	N

Table 1b. Board/Committee Member Roster					
Member Name	**Date First Appointed**	**Date Reappointed**	**Date Term Expires**	**Appointing Authority**	**Type (public or professional)**
Seung Oh, PharmD, President	02/24/2020	03/19/2024	06/01/2027	Governor	Professional
Jessica "Jessi" Crowley, PharmD, Vice President	05/19/2022	04/29/2026	06/01/2029	Governor	Professional
Renee Armendariz Barker, PharmD Treasurer	06/24/2022	04/25/2024	06/01/2027	Governor	Professional
Jeanette Dong	06/19/2025	n/a	06/01/2028	Speaker of the Assembly	Public
R. Jeffrey Hughes	03/19/2024	n/a	06/01/2026	Governor	Public
Kartikeya "KK" Jha, R.Ph.	09/09/2022	05/22/2025	06/01/2028	Governor	Professional
Claudia L. Mercado	04/14/2025	n/a	06/01/2028	California Senate Rules Committee	Public
Jason "J" Newell, MSW	03/19/2024	05/22/2025	06/01/2028	Governor	Public
Ricardo Sanchez	03/18/2025	n/a	06/01/2028	Governor	Public
Satinder Sandhu, PharmD	03/19/2024	04/29/2026	06/01/2029	Governor	Professional
Maria D. Serpa, PharmD	06/19/2018	05/22/2023	06/01/2026	Governor	Professional
Nicole Thibeau, PharmD	07/26/2021	05/22/2025	06/01/2028	Governor	Professional
Vacant	n/a	n/a	06/01/2025	Governor	Public

DRAFT

Board Membership

Seung Oh, PharmD, President

Seung Oh of San Diego was appointed to the California State Board of Pharmacy by Governor Gavin Newsom in 2020 and term will expire June 1, 2027.

Dr. Oh has been a pharmacy supervisor for Sharp Healthcare since 2020. He was a pharmacist-in-charge at Vons Pharmacy in San Diego from 2014-2020, staff pharmacist at Safeway Pharmacy in 2014, and a pharmacist and director of operations at Rainbow Pharmacy from 2013 to 2014.

He earned a Master of Advanced Studies degree in leadership of health care organizations from University of California, San Diego, and a Doctor of Pharmacy degree from University of Arizona. He is a member of the California Pharmacists Association.

Jesssica "Jessi" Crowley, PharmD, Vice President

Jessica "Jessi" Crowley of Los Angeles was appointed to the California State Board of Pharmacy by Governor Gavin Newsom in 2022 and term will expire June 1, 2029.

Crowley has been a staff pharmacist for Pavilions Pharmacy since 2020. She held several positions for CVS Pharmacy from 2010 to 2020, including pharmacist-in-charge, staff pharmacist, and pharmacy intern. Her interests include health equity, racial and social justice, and cultural competence.

Crowley is a member of Lambda Kappa Sigma, United Food and Commercial Workers, the California Pharmacists Association, Los Angeles County Federation of Labor, and Phi Lambda Sigma.

Dr. Crowley earned a Doctor of Pharmacy degree from MCPHS University School of Pharmacy – Boston.

Renee Armendariz Barker, PharmD, Treasurer

Renee Armendariz Barker, of San Carlos, was appointed to the California State Board of Pharmacy by Governor Gavin Newsom in 2022 and term will expire June 1, 2027.

Dr. Armendariz Barker has been sterile products manager at Lucile Packard Children's Hospital Stanford since 1998. She is a member of the California Society of Health System Pharmacists and the American Society of Health System Pharmacists.

Dr. Armendariz Barker earned a Doctor of Pharmacy degree from the University of California, San Francisco.

DRAFT

Jeanette Dong, Public Member

Jeanette Dong was appointed to the California Board of Pharmacy as a Public Board Member by the California Speaker of the Assembly in 2025 and term will expire on June 1, 2028.

Jeanette is currently the Chief Strategy Officer for Alameda Health System, a public safety net hospital system in Alameda County.

Ms. Dong has an expansive career including positions with the California State Assembly, Alameda County, The Port of Oakland and Asian Health Services/La Clinica de la Raza. Her area of expertise includes government affairs, philanthropy, health care, social services, advancement and transportation. Jeanette has held several appointments from Assembly Speakers and other state-elected/appointed officials: California Board of Registered Nursing, California Public Health Advisory Committee, Member, California Public Utilities Commission Workforce Development Task Force and the California Health and Wellness Task Force (SDE) and numerous other appointments in San Francisco and Oakland.

Ms. Dong was also the recipient of the Pioneer Award from East Bay Innovations, Women Warrior Award and the American Lung Association of the East Bay Community Leader Award.

Jeanette is a graduate of the University of California, Berkeley and received her master's degree from Columbia University. She was also an APPAM Sloan Fellow at Harvard University and a Coro Foundation Fellow.

R. Jeffrey Hughes, Public Member

Jeff Hughes, of Oceanside, has been appointed to the State Board of Pharmacy and is serving his one-year grace period.

Hughes has been a Wellness Business Agent at the Orange County Professional Firefighters IAFF Local 3631 since 2020. He was a Fire Captain at the Orange County Fire Authority from 1994 to 2020 and a Firefighter/Engineer for the City of Buena Park Fire Department from 1985 to 1994.

Kartikeya "KK" Jha, Pharmacist

Kartikeya "KK" Jha, of Fresno, was appointed to the California State Board of Pharmacy by Governor Gavin Newsom and term will expire June 1, 2028.

Jha has been District Director of Operations at Omnicare – a CVS Health Company since 2019. He was Director of Operations at NimbleRx from 2018 to 2019. Jha earned a Master of Science degree in Pharmacology and Toxicology from Long Island University.

Claudia L. Mercado, Public Member

Claudia L. Mercado was appointed to the California Board of Pharmacy as a Public Board Member by the California Senate Rules Committee in 2025 and term will expire June 1, 2028.

A longtime advocate for public health, Claudia previously served for nearly 11 years on the Osteopathic Medical Board of California. She brings extensive experience in healthcare access, regulatory oversight, and community-centered leadership.

She is the founder of Vervida, a Latina-owned mineral supplements brand dedicated to empowering wellness through science-backed nutrition, and Calibueno, a California cannabis company focused on cultural equity and economic inclusion. Raised in the Bay Area, Claudia's journey embodies resilience, cultural pride, and a lifelong commitment to advancing health equity, consumer safety, and opportunity for underserved communities.

She holds both an MBA and BA from Mills College and is a proud participant in the Stanford Graduate School of Business Latino Business Action Network (LBAN) program.

Jason "J" Newell, MSW, Public Member

Jason Newell MSW, of Sacramento, has been appointed to the California Board of Pharmacy and term will expire June 1, 2028.

Newell founded and co-founded several businesses including 3 non-profits over the last 22 years. Most recently, Newell was Principal and Co-Founder of System2Solutions since 2020. He was also Co-Founder and remains Program Director of Leveraging Equal Access Program since 2015. Newell attended the University of California, Davis and The Academy of Art Colleges earning a Bachelor of Fine arts and attained a Master of Social Work (emphasis on community mental health) degree from California State University, Hayward.

Ricardo Sanchez, Public Member

Ricardo Sanchez of Hollister was appointed to the California State Board of Pharmacy by Governor Gavin Newsom in 2025 and term will expire June 1, 2028.

Mr. Sanchez has been an Investigator at the California Department of Motor Vehicles since 1989. He is the Chief Financial Officer for the California Statewide Law Enforcement Association and a Member of the San Benito Masonic Temple #211, Order of Eastern Star, Athena #46, California Mexican American Veteran Memorial Beautification and Enhancement Committee and El Soldado Latino. Sanchez earned a Bachelor of Arts degree in Criminal Justice from Union Institute and University.

DRAFT

Satinder Sandhu, PharmD

Satinder Sandhu, of Davis, has been appointed to the State Board of Pharmacy and term will expire June 1, 2029.

Sandhu has been Area Healthcare Supervisor of Northern California for Walgreens since 2019. He held multiple positions with Walgreens from 1992 to 2019, including District Manager, District Pharmacy Supervisor and Pharmacy Manager. Sandhu earned a Doctor of Pharmacy degree from the University of the Pacific.

Maria D. Serpa, PharmD

Maria D. Serpa of Elk Grove was appointed to the California State Board of Pharmacy by Gov. Edmund G. Brown Jr. in 2018 and reappointed by Gov. Gavin Newsom in 2023 and is currently serving her one-year grace period.

Dr. Serpa held several positions at Sutter Medical Center, Sacramento over 25 years and contributed to pharmacy system initiatives at Sutter Health. Her accomplishments include standardization of medication management technologies, regulatory operations and pharmacy construction. She previous held positions of system-support, pharmacy services manager, quality assurance and investigational drug pharmacist. Prior to coming to Sacramento, she worked at Grossmont Hospital (Sharp Healthcare) in San Diego as pharmacy program coordinator of clinical services and staff pharmacist.

Dr. Serpa is a past president of the California Society of Health-System Pharmacists and a fellow of both the American Society of Health-System Pharmacists and the California Society of Health-Systems Pharmacists.

She earned a Doctor of Pharmacy degree from University of the Pacific and completed two residencies at University of California, San Diego, Medical Center (clinical pharmacy and critical care).

Nicole Thibeau, PharmD

Nicole D. Thibeau of Los Angeles was appointed to the California State Board of Pharmacy by Governor Gavin Newsom in July 2021 and term will expire June 1, 2028.

Dr. Thibeau has been director of pharmacy services at the Los Angeles LGBT Center since 2013 and is a member of the policy team, specializing in health services. She was pharmacist in charge at Target Pharmacy from 2012 to 2013 and pharmacist in charge at CVS Pharmacy from 2009 to 2012.

She is an advocate for the LGBTQ+ and disability communities. She specializes in HIV and transgender medicine and serves on committees at the state and national level regarding

DRAFT

the 340b drug discount program and pharmacy operations. She earned a Doctor of Pharmacy degree from the Massachusetts College of Pharmacy and Allied Health Sciences.

Major Changes

Change in Leadership

The Board's Executive Officer, Anne Sodergren, has served in this role since 2020. The Board's Deputy Executive Officer, Julia Ansel, has served in her position since 2023 and previously held a key leadership role as Chief of Enforcement. The Board's executive leadership team also includes a Chief of Enforcement for Compounding and Compliance, a Chief of Enforcement for Drug Diversion, Fraud, and Prescription Drug Abuse, a Chief of Licensing, and a Chief of Legislation, Policy, and Public Affairs.

Strategic Plan

The Board is currently working on updating its Strategic Plan covering 2027 through 2031. The plan was a joint effort between Board members, staff and the public to identify key issues and create action plans. As part of its process, the Board leveraged its prior strategic plan and analyzed trends in pharmacy practice, consumer needs and health care.

Board-Sponsored Legislation and Legislation Affecting the Board

Consumer protection extends beyond the enforcement of legal requirements; it also involves the development and implementation of strategies that safeguard consumers, address the misuse and abuse of prescription drugs, and maintain the integrity of the drug supply chain to prevent the introduction of counterfeit or adulterated medications. As a regulator of a dynamic and evolving profession, the Board remains proactive in ensuring that outdated laws are amended or repealed, while advocating for new legislation that reflects emerging practices and addresses evolving issues. The Board continuously evaluates legislation related to licensing and enforcement, working to secure the necessary tools to effectively protect consumers. Below is a summary of Board-sponsored legislation, along with key legislation affecting the Board's jurisdiction and operations.

2025 Legislation

Enacted Legislation Impacting the Board

- AB 82 (Ward, Chapter 679, Statutes of 2025) Health Care: Legally Protected Health Care Activity
- AB 144 (Committee on Budget, Chapter 105, Statutes of 2025) Health
- AB 260 (Aguiar-Curry, Chapter 136, Statutes of 2025) Sexual and Reproductive Health Care
- AB 309 (Zbur, Chapter 685, Statutes of 2025) Hypodermic Needles and Syringes
- AB 447 (Gonzalez, Chapter 363, Statutes of 2025) Emergency Room Patient Prescriptions
- AB 1503 (Berman, Chapter 196, Statutes of 2025) Pharmacy

DRAFT

- SB 40 (Wiener, Chapter 737, Statutes of 2025) Health Care Coverage: Insulin
- SB 41 (Wiener, Chapter 605, Statutes of 2025) Pharmacy Benefits
- SB 306 (Becker, Chapter 408, Statutes of 2025) Health Care Coverage: Prior Authorizations
- SB 470 (Laird, Chapter 222, Statutes of 2025) Bagley-Keene Open Meeting Act: Teleconferencing
- SB 497 (Wiener, Chapter 764, Statutes of 2025) Legally Protected Health Care Activity
- SB 568 (Niello, Chapter 322, Statutes of 2025) Pupil Health: Epinephrine Delivery Systems: School sites and Childcare Programs

2026 Legislation

Enacted Legislation Impacting the Board

- AB1587 (Ta, Chapter 69, Statutes of 2026) Prescription Drug Refills: Prescriber
- AB 1775 (Ward, Chapter 467, Statutes of 2026) Veterans
- AB 1778 (Patterson, Chapter 121, Statutes of 2026)
- AB 1794 (Ransom, Chapter 546, Statutes of 2026) Pharmacy: Enteral Nutrition Supplements or Replacements
- AB 1811 (Rogers, Chapter 549, Statutes of 2026) Health Professionals
- AB 1887 (Zbur, Chapter 557, Statutes of 2026)
- AB 1979 (Bonta, Chapter 854, Statutes of 2026)
- SB 964 (Smallwood-Cuevas, Chapter 663, Statutes of 2026) Prescription Drug Coverage: Dose Adjustments
- SB 1023 (Laird, Chapter 470, Statutes of 2026) Health Care Coverage: Antiretroviral Drugs, Drug Devices, and Drug Products
- SB 1094 (Weber-Pierson, Chapter 1007, Statutes 2026) Prescription Drugs
- SB 1347 (Niello, Chapter 703, Statutes 2026) Pupil Health: Emergency Stock Albuterol Inhalers

Regulation Changes

Regulations referenced in this report are located in Division 17 of Title 16, California Code of Regulations unless otherwise noted.

2025 Regulation Changes

- Effective July 1, 2025: Add Section 1700 – Digital Signatures
- Effective October 1, 2025: Repeal sections 1708.3, 1708.4, 1708.5 of Title 16, Division 17, Article 2 of the California Code of Regulations; Repeal 1735 et seq of Title 16, Division 17, Article 4.5 of the California Code of Regulations; Repeal 1751 et seq of Title 16, Division 17, Article 7 of the California Code of Regulations; Add new sections 1735 et seq of Title 16, Division 17, Article 4.5 of the California Code of Regulations; Add new sections/Article 1736 et seq of Title 16, Division 17, Article 4.6 of the California Code of Regulations; Add new sections/Article 1737 et seq of Title 16, Division 17, Article 4.7 of the California Code of Regulations; Add new sections/Article 1738 et seq of Title 16, Division 17, Article 4.8 of the California Code of Regulations

DRAFT

2026 Regulation Changes

- Effective April 1, 2026: Amend Section 1708.2 – Discontinuance of Business
- Effective April 1, 2026: Amend Section 1713 – Automated Patient Delivery System (APDS) Consultation
- Approved by Office of Administrative Law April 15, 2026: Amend Section 1760 – Disciplinary Guidelines

Pending Regulations the Board Currently Has in Various Stages of Promulgation

- Amend Section 1715.1 – ADDS Self-Assessment – Board voted 4/29-30/26 to repeal;
- Amend Section 1713 – Automated Patient Delivery System Consultation – Board voted 4/24/26 to initiate; effective 4/1/26
- Amend Section 1707.4 – Central Fill Pharmacies – Board voted to initiate 8/1/24; 15-day comment period ending 10/2/26
- Repeal Sections 1708.3. 1708.4, 1708.5, 1735 et seq and 1751 et seq and Add Sections 1735 et seq, 1736 et seq, 1737 et seq, and 1738 et seq – Compounding Drug Preparations – Board approved text/initiate April 19-20, 2023; effective 10/1/25
- Amend Section 1709.1 – Designation of Pharmacist-in-Charge – effective 4/1/25
- Amend Section 1700 – Digital Signatures – effective 7/1/25
- Amend Section 1708.2 – Discontinuance of Business – effective 4/1/26
- Amend Section 1749(c) – Pharmacy Technician Fee Schedule – effective 1/1/25
- Amend Section 1747 – HIV Preexposure Prophylaxis Furnishing – Permanent – effective 1/31/25; In process of repealing 2026
- Amend Section 1746.6 - Medication Assisted Treatment Protocol – Withdrawn 2/20/26
- Amend Section 1793.65 – Pharmacy Technician Certification – effective 7/8/26
- Amend Sections 1715 and 1784 – Pharmacy, Hospital and Wholesaler Self-Assessment
- Amend Section 1711 – Quality Assurance – Withdrawn 7/18/25; In the Process of Submitting 2026
- Add Section 1750 – Outsourcing Self-Assessment – Board Withdrew Motion to Initiate 6/2026

Major Studies

In 2026, DCA completed a fee analysis of all the Board's fees and determined the Board is not recovering the full cost of services based on the current fees established in section 1749 of Title 16, Division 17, Article 6 of the California Code of Regulations. Based on the information provided in DCA's fee analysis, the Board approved to initiate a rulemaking which identifies areas within the fee schedule that require realignment to restore the Board's fund balance to the required statutory one-year reserve level.

Business and Professions Code (BPC) section 4113.1 establishes requirements for a community pharmacy to report medication errors to an entity approved by the Board. In September 2024, the Board approved the Institute for Safe Medication Practices (ISMP), an ECRI Company, as the entity to receive and review medication error reports under BPC section 4113.1 to the California Medication Error Reporting (CAMER) system. The Board advised licensees that medication errors that occur on or after September 1, 2025, must be reported

to the CAMER system consistent with legal requirements established. The Board has received and presented the following reports at Board meetings:

- Semi-Annual Report (June – December 2025*) - January 2026 Board meeting
- Quarterly Report (January – March 2026) - June 2026 Board meeting
- Annual Report (July 2025 – June 2026*) - October 2026 Board meeting

** Licensees were required to report medication errors that occurred on or after September 1, 2025*

National Associations

The Board is a member of the National Association of Boards of Pharmacy (NABP) and, as a full member, holds one vote on matters before the association. The Board also participates in NABP District 8, where Seung Oh, PharmD, Board President, serves as Treasurer, and Anne Sodergren, the Board's Executive Officer, serves as Chairperson.

The Board is also a member of the National Association of State Controlled Substances Authorities (NASCSA) and the Council on Licensure, Enforcement and Regulation (CLEAR), but does not have voting privileges.

Committees, Workshops and Working Group Involvement:

The Board values the opportunity to participate in committees and efforts undertaken at the national level impacting the practice of pharmacy as a means to advance California's consumer protection priorities.

Committee, Workshops and Working Group Participation

- NABP – Advisory Committee on Examination (ACE): Anne Sodergren
- NABP – Task Force to Assess Expanding Access to NABP Competence Assessment Examinations: Seung Oh, PharmD
- NABP Annual Meeting: Anne Sodergren and Seung Oh, PharmD
- NABP – District 8: Anne Sodergren, Chairperson; Seung Oh, PharmD, Treasurer

National Association of Boards of Pharmacy Meetings Attended

- NABP ACE: March 11-13, 2025 – Mount Prospect, IL – Anne Sodergren
- NABP Annual Meeting: May 12-16, 2025 – Fort Lauderdale, FL – Anne Sodergren and Seung Oh, PharmD
- NABP District 8: October 5-7, 2025 – St. Louis, MO – Anne Sodergren and Seung Oh, PharmD
- NABP Annual Meeting: May 12-15, 2026 – Boston, MA – Anne Sodergren and Seung Oh, PharmD

National Exam Involvement

The Board does not have specific representation on the national exam committee. However, former members of the Competency Committee (which develops the California exam) participate in the scoring and analysis of the NAPLEX. As stated previously, the executive

DRAFT

officer serves on the ACE Committee, responsible for review of examinations administered by the NABP.

Section 2 – Fiscal and Staff

Fund Appropriation
Business and Professions Code section 4406 provides that all fees collected on behalf of the Board and all receipts of every kind and nature shall be credited to the Pharmacy Board Contingent Fund, which is created in this section. The contingent fund shall be available, upon appropriation of the Legislature for use of the Board.

Board Senate Bill 212 (Jackson, Chapter 1002, Statutes of 2018), established the Pharmaceutical and Sharps Stewardship Fund, and provided provisions for the Board to seek reimbursement from the fund for purposes of administering and enforcing the measure.

Reserve Level/Spending
Business and Professions Code section 4400(p), provides that it is the intent of the Legislature that, in setting fees, the Board shall seek to maintain a reserve in its fund equal to approximately one year's operating expenditure. At the end of Fiscal Year 2025/26, the Board's reserve remains below this statutory target. The reserve totaled 9.5 months, or approximately $32.5 million, compared with authorized annual expenditures of $35.4 million as detailed in the summary below and Table 2. Fund Condition.

General Fund Loans
The Board loaned $2.4M to the general fund in FY 2019/20. The Board was repaid in FY 2024/25.

Fund Condition Projections		
	FY 2024/25	**FY 2025/26**
Fund Balance	$26,217	$32,460
Months in Reserve	8.9	9.5

Table 2. Fund Condition		
	FY 2024/25	**FY 2025/26**
Beginning Balance	$19,520	$26,914
Revenues and Transfers	$38,163	$41,025
Total Resources	$57,683	$67,939
Budget Authority	$34,699	$35,690
Expenditures	$33,929	$35,479

DRAFT

Table 2. Fund Condition		
	FY 2024/25	**FY 2025/26**
Loans to General Fund	$0	$0
Accrued Interest, Loans to General Fund	$63	$0
Loans Repaid From General Fund	$2,400	$0
Fund Balance	$26,217	$32,460
Months in Reserve	8.9	9.5

Table 4. Fee Schedule and Revenue							
Fee	**Current Fee Amount**	**Statutory Limit**	**FY 2024/25 Revenue**	**FY 2025/26 Revenue**	**FY 2026/27 Revenue**	**FY 2027/28 Revenue**	**% of Total Revenue**
Initial Individual Applications							
Advanced Pharmacist Practitioner (APH)	$300	$418	50	61			0.16%
Designated Paramedic (DPM)	$350	$494	0	0			0.00%
Designated Representative-Wholesaler (EXC)	$345	$485	138	151			0.40%
Designated Representative - Vet (EXV)	$345	$485	1	2			0.01%
Designated Representative-3PL (DRL)	$345	$485	36	47			0.13%
Designated Representative-Reverse Distributor (DRR)	$345	$485	2	2			0.01%
Intern Pharmacist (INT)	$175	$245	300	241			0.64%
Intern Pharmacist Application Extension (INT)	$175	$175	27	29			0.08%
Pharmacist Exam	$260	$285	434	659			1.76%
Pharmacist Exam Retake	$260	$285	255	348			0.93%
Pharmacist Licensure (RPH)	$195	$215	287	314			0.84%
Pharmacy Technician (TCH)	$120	$165	999	781			2.08%

DRAFT

Table 4. Fee Schedule and Revenue							
Fee	**Current Fee Amount**	**Statutory Limit**	**FY 2024/25 Revenue**	**FY 2025/26 Revenue**	**FY 2026/27 Revenue**	**FY 2027/28 Revenue**	**% of Total Revenue**
Initial Facility Applications							
Automated Drug Delivery System (ADD)	$525	$741	58	193			0.51%
Automated Drug Delivery System-Correctional Clinic (ADD)	$500	$705	4	8			0.02%
Automated Drug Delivery System–EMS (ADE)	$150	$380	0	0			0.00%
Automated Patient Dispensing System - 340B Clinic (ADC)	$525	$741	2	3			0.01%
Centralized Hospital Packaging (CHP)	$3,815	$5,318	1	0			0.00%
Centralized Hospital Packaging-Government Owned (CHE)	$3,815	$5,318	0	0			0.00%
Clinic (CLN)	$620	$873	95	91			0.24%
*Clinic-Government-Owned (CLE)	$620	$873	31	19			0.05%
*Clinic-Government Owned Correctional (CLE)	$620	$873	0	0			0.00%
Drug Room (DRM)	$750	$2,000	0	0			0.00%
*Drug Room-Government Owned (DRE)	$750	$2,000	0	0			0.00%
Hospital Pharmacy (HSP)	$750	$2,000	8	11			0.03%
*Hospital Pharmacy-Government-Owned (HPE)	$750	$2,000	2	2			0.01%
Hospital Satellite Compounding Pharmacy (SCP)	$3,875	$5,466	0	0			0.00%
* Hospital Satellite Compounding Pharmacy Government-Owned (SCE)	$3,875	$5,466	0	19			0.05%
Hypodermic Needle (HYP)	$550	$775	5	3			0.01%
Licensed Correctional Pharmacy (LCF)	$750	$2,000	0	0			0.00%

DRAFT

Table 4. Fee Schedule and Revenue							
Fee	**Current Fee Amount**	**Statutory Limit**	**FY 2024/25 Revenue**	**FY 2025/26 Revenue**	**FY 2026/27 Revenue**	**FY 2027/28 Revenue**	**% of Total Revenue**
Outsourcing Facility (OSF)	$25,000	$35,256	10	50			0.13%
Nonresident Outsourcing Facility (NSF)	$28,500	$42,318	102	200			0.53%
Pharmacy (PHY)	$750	$2,000	264	243			0.65%
Pharmacy Chain (PHY)	VAR	VAR	570	9			0.02%
*Pharmacy- Government-Owned (PHE)	$750	$2,000	7	7			0.02%
Nonresident Pharmacy (NRP)	$2,427	$3,424	188	300			0.80%
Remote Dispense Site Pharmacy (PHR)	$1,730	$2,440	0	0			0.00%
Sterile Compounding (LSC)	$3,875	$5,466	184	202			0.54%
*Sterile Compounding-Government-Owned (LSE)	$3,875	$5,466	34	8			0.02%
Nonresident Sterile Compounding (NSC)	$8,500	$16,502	113	162			0.43%
Surplus Medication Collection Distribution Intermediary (SME)	$300	$300	0	0			0.00%
Third-Party Logistics Provider (TPL)	$1,000	$1,411	4	12			0.03%
Nonresident Third-Party Logistics Provider (NPL)	$1,000	$1,411	32	58			0.15%
Vet Food-Animal Drug Retailer (VET)	$610	$825	0	1			0.00%
Wholesaler (WLS)	$1,000	$1,411	47	55			0.15%
Wholesaler - Emergency Medical Service Provider (WLS)	$810	$1,143	0	0			0.00%
*Wholesaler-Government-Owned (WLE)	$1,000	$1,411	2	0			0.00%
Nonresident Wholesaler (OSD)	$1,000	$1,411	133	149			0.40%
Miscellaneous Fees							
Change of Address/ Trade style Name (Facility Only)	$206	$282	0	0			0.00%

DRAFT

Table 4. Fee Schedule and Revenue							
Fee	**Current Fee Amount**	**Statutory Limit**	**FY 2024/25 Revenue**	**FY 2025/26 Revenue**	**FY 2026/27 Revenue**	**FY 2027/28 Revenue**	**% of Total Revenue**
Change of Designated Representative-in-Charge (DRIC)	$250	$353	32	42			0.11%
Change of Pharmacist-in-Charge (PIC)	$250	$353	379	463			1.23%
Change of Responsible Manager (RMG)	$250	$353	9	10			0.03%
Change of Permit	$395	$557	593	1,071			2.85%
Duplicate/Replacement Certificate	$75	$100	104	118			0.31%
Evaluation of Continuing Education Courses	$40 per hour	$40 per hour	0	0			0.00%
Regrade of Pharmacist Examination	$115	$200	0	1			0.00%
Retired Pharmacist License	$50	$100	14	17			0.05%
Transfer of Intern Hours/ License Verification	$120	$168	28	41			0.11%
Temporary License Fees							
Drug Room (DRM/DRE)	$1,600	$2,740	0	0			0.00%
Licensed Correctional Pharmacy (LCF)	$1,600	$2,740	0	0			0.00%
Hospital Pharmacy (HSP)	$1,600	$2,740	10	22			0.06%
*Hospital Pharmacy-Government-Owned (HPE)	$1,600	$2,740	3	2			0.01%
Hospital Satellite Compounding Pharmacy (SCP)	$1,065	$1,503	0	1			0.00%
* Hospital Satellite Compounding Pharmacy Government-Owned (SCE)	$1,065	$1,503	0	3			0.01%
Outsourcing Facility (OSF)	$4,000	$5,642	1	4			0.01%
Nonresident Outsourcing Facility (NSF)	$4,000	$5,642	1	12			0.03%
Pharmacy (PHY)	$1,600	$2,740	372	1,193			3.18%

DRAFT

Table 4. Fee Schedule and Revenue							
Fee	**Current Fee Amount**	**Statutory Limit**	**FY 2024/25 Revenue**	**FY 2025/26 Revenue**	**FY 2026/27 Revenue**	**FY 2027/28 Revenue**	**% of Total Revenue**
* Pharmacy-Government-Owned (PHE)	$1,600	$2,740	3	5			0.01%
Nonresident Pharmacy (NRP)	$2,000	$2,469	106	170			0.45%
Remote Dispense Site Pharmacy (PHR)	$890	$1,199	0	0			0.00%
Sterile Compounding (LSC)	$1,065	$1,503	38	38			0.10%
*Sterile Compounding-Government-Owned (LSE)	$1,065	$1,503	3	0			0.00%
Nonresident Sterile Compounding (NSC)	$1,500	$2,000	15	21			0.06%
Third-Party Logistics Provider (TPL)	$715	$1,009	3	4			0.01%
Nonresident Third-Party Logistics Provider (NPL)	$715	$1,009	12	21			0.06%
Vet Food-Animal Drug Retailer Temporary (VET)	$520	$732	0	0			0.00%
Wholesaler (WLS)	$715	$1,009	16	13			0.03%
* Wholesaler-Government-Owned (WLE)	$715	$1,009	1	0			0.00%
Nonresident Wholesaler (OSD)	$715	$1,009	36	50			0.13%
Renewal Fees							
Biennial							
Advanced Pharmacist Practitioner (APH)	$300	$418	199	205			0.55%
Designated Paramedic (DPM)	$200	$292	0	0			0.00%
Pharmacist License (RPH)	$450	$450	10,929	10,443			27.82%
Pharmacy Technician (TCH)	$150	$180	4,913	4,183			11.14%
Annual							
Designated Representative-Wholesaler (EXC)	$388	$547	848	990			2.64%

DRAFT

Table 4. Fee Schedule and Revenue							
Fee	**Current Fee Amount**	**Statutory Limit**	**FY 2024/25 Revenue**	**FY 2025/26 Revenue**	**FY 2026/27 Revenue**	**FY 2027/28 Revenue**	**% of Total Revenue**
Designated Representative-Vet (EXV)	$388	$547	19	22			0.06%
Designated Representative-3PL (DRL)	$388	$547	149	202			0.54%
Designated Representative Reverse Distributor (DRR)	$388	$547	4	7			0.02%
Automated Drug Delivery System (ADD)	$453	$639	254	505			1.35%
Automated Drug Delivery System-Correctional Clinic (ADD)	$400	$561	0	0			0.00%
Automated Drug Delivery System–EMS (ADE)	$200	$273	0	0			0.00%
Automated Patient Dispensing System - 340B Clinic (ADC)	$453	$639	0	1			0.00%
Centralized Hospital Packaging (CHP)	$2,912	$4,107	16	20			0.05%
Centralized Hospital Packaging-Government Owned (CHE)	$2,912	$4,107	2	3			0.01%
Clinic (CLN/CLE)	$400	$561	831	925			2.46%
Clinic-Government Owned Correctional (CLE)	$400	$561	0	0			0.00%
Drug Room (DRM/DRE)	$1,025	$2,000	10	14			0.04%
Hospital Pharmacy (HSP/HPE)	$1,025	$2,000	244	271			0.72%
Hospital Satellite Compounding Pharmacy (SCP/SCE)	$4,085	$5,762	15	37			0.10%
Hypodermic Needle (HYP)	$400	$561	66	80			0.21%
Licensed Correctional Pharmacy (LCF)	$1,025	$2,000	50	55			0.15%
Pharmacy (PHY/PHE)	$1,025	$2,000	5,630	5,443			14.5%
Nonresident Pharmacy (NRP)	$1,025	$3,424	493	530			1.41%
Outsourcing Facility (OSF)	$25,000	$41,366	27	75			2.02%

DRAFT

Table 4. Fee Schedule and Revenue							
Fee	**Current Fee Amount**	**Statutory Limit**	**FY 2024/25 Revenue**	**FY 2025/26 Revenue**	**FY 2026/27 Revenue**	**FY 2027/28 Revenue**	**% of Total Revenue**
Nonresident Outsourcing Facility (NSF)	$28,500	$46,353	393	570			1.52%
Remote Dispense Site Pharmacy (PHR)	$1,025	$2,000	2	2			0.01%
Sterile Compounding (LSC)	$4,085	$5,762	2,023	3,178			8.47%
Surplus Medication Collection and Distribution Intermediary (SME)	$300	$300	0	0			0.00%
Nonresident Sterile Compounding (NSC)	$8,500	$17,040	264	417			1.11%
Third-Party Logistics Provider (TPL)	$1,000	$1,411	31	35			0.09%
Nonresident Third-Party Logistics Provider (NPL)	$1,000	$1,411	134	158			0.42%
Vet Food-Animal Drug Retailer (VET)	$460	$561	7	7			0.02%
Wholesaler (WLS/WLE)	$1,000	$1,411	356	396			1.05%
Wholesaler - Emergency Medical Services Provider (WLS)	$810	$1,143	0	0			0.00%
Nonresident Wholesaler (OSD)	$1,000	$1,411	641	758			1.11%
Renewal Delinquency Fees							
Biennial							
Advanced Pharmacist Practitioner (APH)	$150	$150	3	3			0.01%
Designated Paramedic (DRM)	$100	$150	0	0			0.00%
Pharmacist License (RPH)	$150	$150	64	74			0.20%
Pharmacy Technician (TCH)	$150	$150	118	108			0.29%
Annual							
Designated Representative - Wholesaler (EXC)	$150	$150	17	24			0.06%
Designated Representative-Vet (EXV)	$150	$150	1	1			0.00%

DRAFT

Table 4. Fee Schedule and Revenue							
Fee	**Current Fee Amount**	**Statutory Limit**	**FY 2024/25 Revenue**	**FY 2025/26 Revenue**	**FY 2026/27 Revenue**	**FY 2027/28 Revenue**	**% of Total Revenue**
Designated Representative-3PL (DRL)	$150	$150	1	5			0.01%
Designated Representative-Reverse Distributor (DRR)	$150	$150	0	0			0.00%
Automated Drug Delivery System (ADD)	$150	$150	2	2			0.01%
Automated Drug Delivery System - Correctional Clinic (ADD)	$150	$150	0	0			0.00%
Automated Drug Delivery System–EMS (ADE)	$100	$150	0	0			0.00%
Automated Patient Dispensing System - 340B Clinic (ADC)	$150	$150	0	0			0.00%
Drug Room (DRM/DRE)	$150	$150	0	0			0.00%
Centralized Hospital Packaging (CHP)	$150	$150	0	0			0.00%
Centralized Hospital Packaging- Government Owned (CHE)	$150	$150	0	0			0.00%
Clinic (CLN/CLE)	$150	$150	11	13			0.03%
Clinic-Government Owned Correctional (CLE)	$150	$150	0	0			0.00%
Hospital (HSP/HPE)	$150	$150	0	0			0.00%
Hospital Satellite Compounding Pharmacy (SCP/SCE)	$150	$150	0	0			0.00%
Hypodermic Needle (HYP)	$150	$150	4	5			0.01%
Licensed Correctional Pharmacy (LCF)							
Outsourcing Facility (OSF)	$150	$150	0	0			0.00%
Nonresident Outsourcing Facility (NSF)	$150	$150	0	0			0.00%
Pharmacy (PHY)	$150	$150	3	2			0.01%
Nonresident Pharmacy (NRP)	$150	$150	2	2			0.01%

DRAFT

Table 4. Fee Schedule and Revenue							
Fee	**Current Fee Amount**	**Statutory Limit**	**FY 2024/25 Revenue**	**FY 2025/26 Revenue**	**FY 2026/27 Revenue**	**FY 2027/28 Revenue**	**% of Total Revenue**
Remote Dispensing Site Pharmacy (PHR)	$150	$150	0	0			0.00%
Sterile Compounding (LSC)	$150	$150	1	1			0.00%
Nonresident Sterile Compounding (NSC)	$150	$150	0	0			0.00%
Surplus Medication Collection and Distribution Intermediary (SME)	$150	$150	0	0			0.00%
Third-Party Logistics Provider (TPL)	$150	$150	0	0			0.00%
Nonresident Third-Party Logistics Provider (NPL)	$150	$150	0	0			0.00%
Vet Food-Animal Drug Retailer (VET)	$150	$150	0	0			0.00%
Wholesaler (WLS/WLE)	$150	$150	3	3			0.01%
Wholesaler - Emergency Medical Service Provider (WLS)	$150	$150	0	0			0.00%
Nonresident Wholesaler (OSD)	$150	$150	3	5			0.01%

- FY 24/25 Figures based on Revenue Month 13 Fi$Cal Report.
- FY 25/26 Figures based on Revenue Month 13 Fi$Cal Report.

DRAFT

Budget Change Proposals

The Board closely monitors its fund and assesses processes and resources to identify changes necessary to ensure robust consumer protection activities. When resource needs are identified, the Board requests augmentations to its expenditure authority, position authority or both through the BCP process. The Board is very thoughtful in its requests and only seeks augmentations when the issue cannot be resolved through redirection of resources, improved processes, or other means.

Table 5. Budget Change Proposals (BCPs)

BCP ID #	Fiscal Year	Description of Purpose of BCP	Personnel Services				OE&E	
			# Staff Requested (include classification)	# Staff Approved (include classification	$ Requested	$ Approved	$ Requested	$ Approved
111-0	2024/25	Enforcement & Compounding	1.0 Supervisor II 3.0 Inspectors 1.0 Supervising Inspector	1.0 Supervisor II 3.0 Inspectors 1.0 Supervising Inspector	$1,100	$1,100	$165	$165
1111-051	2025/26	Enforcement	1.0 Analyst II 1.0 Office Tech	1.0 Analyst II 1.0 OT	$227	$227	$66	$66
1111-049	2025/26	Regulation	1.0 Analyst II	1.0 Analyst II	$134	$134	$33	$33
1111-035	2026/27	Chief of Licensing	1.0 CEA	1.0 CEA	$218	$218	$33	$33

Staffing Issues and Challenges

Pharmacy law acknowledges the evolving nature of the pharmacy profession, and integral to the Board's mandate of consumer protection is its ability to respond swiftly and effectively to these changes. The Board's most valuable asset is its staff, whose expertise is essential to fulfilling its mission. While the Bureau of Labor Statistics reported a median employee tenure of about 4.1 years as of January 2026, the Board benefits from a dedicated workforce, with 76 employees having more than five years of tenure. This experience fosters a deep understanding of the profession, the Board's mission and operational functions, enabling the Board to carry out its duties with enhanced organizational insight and commitment to its mission.

The Board has 135.2 authorized positions, including 60 licensed pharmacists. These pharmacists, with their diverse education and practice experience, bring invaluable expertise to investigations and risk assessments aimed at protecting patients. Board

DRAFT

inspections are equipped to promptly identify violations that may jeopardize consumer safety and offer technical guidance to licensees on compliance with Board state and federal regulations.

The Board activity encourages staff participation in the Individual Development Process (IDP), which includes opportunities such as the Department's Upward Mobility Program and Analyst Certification Program. The Board is committed to professional development with 20 of its non-pharmacist staff having received at least one promotion since FY 2024/25. In addition, the Board prioritizes cross-training to broaden staff knowledge and to ensure effective succession planning, strengthening its capacity to continue fulfilling its critical regulatory functions.

The Board currently has the following vacancies:

- 1 Legislation Chief (CEA)
- 2 Inspector positions
- 3 Licensing position
- 2 Enforcement position
- 1 Administration position

The Board is committed to the timely recruitment and onboarding of new employees, recognizing that delays in filling vacancies can lead to a backlog of work and disrupt the operations of the Board. To enhance recruitment efforts, the Board's career opportunities are advertised through the DCA's Daily Job Posting notices sent to all DCA employees via email. The Board occasionally advertises high-level management positions through additional channels beyond CalCareers, including specialized publications. However, the Board has faced recruitment challenges related to the eligibility of applicants within the State's hiring examination process.

The Board continues to ensure a more equitable evaluation of screening applicants. Personal identifying information is removed during the screening of applications to mitigate potential biases and foster a more inclusive hiring process.

The Board strives for timely recruitment and uses a robust onboarding program that includes a standardized training plans covering information about the Board and its organizational structure. This plan is then tailored to each new employee's specific duties to ensure all staff receive consistent, relevant information.

Staff Development

The Board believes a well-trained workforce is essential to fulfilling its mission. To support this, the Board provides training aimed at strengthening performance and promoting ongoing professional development. Employees are encouraged to participate in a broad range of learning opportunities, including virtual training delivered through platforms such as Microsoft Teams, teleconferences, and other remote learning formats.

Board staff have at its availability a host of valuable training offered through DCA's Training Unit within the Strategic Organizational Leadership and Individual Development (SOLID). Trainings offered by SOLID's Training Unit include training courses that are diverse and focus

on soft, technical, and job–specific skills. The Training Unit also supports DCA by providing tailored learning elements that embody core competencies as set forth by CalHR. The Board acknowledges the resources offered by DCA's SOLID Training Unit as evidence by the 105 classes taken in FY 24/25 and 100 classes taken in FY 25/26.

The Board also focused on employee training and development as a means to continue to develop talent from within the Board. The Board spent $11,775 in FY 2024/25 and $6,270 in FY 25/26 on external training classes. In addition to in services and DCA training, inspector staff also receive specialized trainings that enable staff to acquire expertise directly from organizations, including the U.S. Food and Drug Administration and the US Pharmacopeia as examples.

Board staff training and development continue to focus on staff members taking Diversity, Equity, Inclusion, and Accessibility (DEIA) training. DCA SOLID Training Unit implemented the DEIA Ambassador Program recognizing employees who demonstrate a commitment to fostering an inclusive and accessible workplace. To earn a recognition badge and certificate, participants must complete a minimum of ten hours of DEIA-approved coursework selected from the provided list of training options. A total of four Board staff completed and received their DEIA Ambassador Program Certificate and Badge.

	No. Courses FY 24/25	No. Attendees FY 24/25	No. Courses FY 25/26	No. Attendees FY 25/26	No. Courses FY 26/27	No. Attendees FY 26/27	No. Courses FY 27/28	No. Attendees FY 27/28
Department Provided Training	105	103	100	111				
External Vendor Training	2	1	21	58				
Internal Staff Training	10	57	1	65				

Training Expenses (not including travel costs)

	FY 24/25	FY 25/26	FY 26/27	FY 27/28
External Vendor Training Costs	$11,775	$6,270		

Section 3 – Licensing Program

The Board's licensees are integral to the delivery of quality health care. They compound, transport, dispense, and store prescription drugs and devices for patients that are essential for patient care and treatment. Pharmacists, as the health care provider, are most educated on pharmaceutical care and management, convey critical information about drug therapy management to their patients and patients' representatives, as well as to other health care providers. In addition, the pharmacist's scope of practice continues to evolve to assume a more active role due to their significant education (at least eight years post high school) and the fact that they are readily accessible to consumers.

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Advanced Pharmacist Practitioner (APH)	Active[1]	1431	1538		
	Out of State	37	44		
	Out of Country	1	1		
	Delinquent/Expired	77	97		
	Retired Status if applicable	0	0		
	Inactive	5	5		
	Other[2]	0	0		
Designated Paramedic (DPM)	Active[1]	3	3		
	Out of State	1	1		
	Out of Country	0	0		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	0	0		
	Other[2]	0	0		
Designated Representative Wholesaler (EXC)	Active[1]	2864	2871		
	Out of State	1506	1552		
	Out of Country	0	2		
	Delinquent/Expired	166	112		
	Retired Status if applicable	N/A	N/A		
	Inactive	0	0		
	Other[2]	27	5		

DRAFT

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Designated Representative Veterinary Food-Animal Drug Retailer (EXV)	Active[1]	57	58		
	Out of State	1	1		
	Out of Country	0	0		
	Delinquent/Expired	3	1		
	Retired Status if applicable	N/A	N/A		
	Inactive	0	0		
	Other[2]	0	0		
Designated Representative-3PL (DRL)	Active[1]	598	623		
	Out of State	464	475		
	Out of Country	1	1		
	Delinquent/Expired	40	23		
	Retired Status if applicable	NA	N/A		
	Inactive	0	0		
	Other[2]	0	0		
Designated Representative-Reverse Distributor (DRR)	Active[1]	23	22		
	Out of State	19	18		
	Out of Country	0	0		
	Delinquent/Expired	1	3		
	Retired Status if applicable	N/A	N/A		
	Inactive	0	0		
	Other[2]	0	0		
Intern Pharmacist (INT)	Active[1]	4140	4043		
	Out of State	225	206		
	Out of Country	3	2		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	0	0		
	Other[2]	0	1		

DRAFT

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Pharmacist (RPH)	Active[1]	47049	47680		
	Out of State	5383	5637		
	Out of Country	115	110		
	Delinquent/Expired	2833	2685		
	Retired Status if applicable	2909	3223		
	Inactive	1194	1168		
	Other[2]	46	11		
Pharmacy Technician (TCH)	Active[1]	64050	63383		
	Out of State	1282	1252		
	Out of Country	3	1		
	Delinquent/Expired	1826	2017		
	Retired Status if applicable	N/A	N/A		
	Inactive	169	288		
	Other[2]	238	276		
Temp Military-Advanced Pharmacist Practitioner (TAP)	Active[1]	0	0		
	Out of State	0	0		
	Out of Country	0	0		
	Delinquent/Expired	N/A	N/A		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	N/A	N/A		
Temp Military-Designated Paramedic (TDP)	Active[1]	0	0		
	Out of State	0	0		
	Out of Country	0	0		
	Delinquent/Expired	N/A	N/A		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	N/A	N/A		

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Temp Military-Designated Representative-Wholesaler (TEX)	Active[1]	0	0		
	Out of State	0	0		
	Out of Country	0	0		
	Delinquent/Expired	N/A	N/A		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	N/A	N/A		
Temp Military-Designated Representative- 3PL (TDR)	Active[1]	0	0		
	Out of State	0	0		
	Out of Country	0	0		
	Delinquent/Expired	N/A	N/A		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	N/A	N/A		
Temp Military-Designated Representative-Reverse Distributor (TRR)	Active[1]	0	0		
	Out of State	0	0		
	Out of Country	0	0		
	Delinquent/Expired	N/A	N/A		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	N/A	N/A		
Temp Military-Intern Pharmacist (TIN)	Active[1]	0	0		
	Out of State	0	0		
	Out of Country	0	0		
	Delinquent/Expired	N/A	N/A		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	N/A	N/A		

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Temp Military-Pharmacist (TRP)	Active[1]	0	0		
	Out of State	0	0		
	Out of Country	0	0		
	Delinquent/Expired	N/A	N/A		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	N/A	N/A		
Temp Military-Pharmacy Technician (TTC)	Active[1]	6	10		
	Out of State	0	0		
	Out of Country	0	0		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	0	0		
	Other[2]	N/A	N/A		
Automated Drug Delivery System (ADD)	Active[1]	1183	1321		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	9	23		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Automated Drug Delivery System EMS (ADE)	Active[1]	0	0		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	1	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		

DRAFT

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Automated Patient Dispensing System 340B Clinic (ADC)	Active[1]	3	1		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	0	0		
	Other[2]	0	0		
Centralized Hospital Packaging (CHP/CHE)	Active[1]	10	**9**		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Clinic (CLN/CLE)	Active[1]	2349	**2410**		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	40	56		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Exempt Hospital (Drug Room) (DRM/DRE)	Active[1]	29	28		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	1		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		

DRAFT

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Hospital Pharmacy (HSP/HPE)	Active[1]	484	485		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	1		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Hospital Satellite Compounding Pharmacy (SCP/SCE)	Active[1]	9	11		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Hypodermic Needle and Syringe (HYP/HYE)	Active[1]	192	191		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	26	16		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Licensed Correctional Facility (LCF)	Active[1]	54	54		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		

DRAFT

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Outsourcing Facility (OSF)	Active[1]	3	4		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Nonresident Outsourcing Facility (NSF)	Active[1]	20	20		
	Out of State	20	20		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	1		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Pharmacy (PHY/PHE)	Active[1]	6033	5726		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	14	7		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Nonresident Pharmacy (NRP)	Active[1]	580	582		
	Out of State	580	582		
	Out of Country	N/A	N/A		
	Delinquent/Expired	19	10		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		

DRAFT

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Remote Dispensing Site Pharmacy (PHR)	Active[1]	3	3		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Sterile Compounding Pharmacy (LSC/LSE)	Active[1]	799	806		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	7	1		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Nonresident Sterile Compounding Pharmacy (NSC)	Active[1]	52	55		
	Out of State	52	55		
	Out of Country	N/A	N/A		
	Delinquent/Expired	2	3		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Surplus Medication Distribution Intermediary (SME)	Active[1]	1	1		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		

DRAFT

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Third-Party Logistics Provider (TPL)	Active[1]	40	37		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	3	3		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Nonresident Third-Party Logistics Provider (NPL)	Active[1]	172	180		
	Out of State	172	180		
	Out of Country	N/A	N/A		
	Delinquent/Expired	2	9		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Veterinary Food-Animal Drug Retailer (VET)	Active[1]	16	16		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	0	0		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		
Wholesaler (WLS/WLE)	Active[1]	417	401		
	Out of State	N/A	N/A		
	Out of Country	N/A	N/A		
	Delinquent/Expired	43	34		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		

DRAFT

Table 6. Licensee Population					
License Type		**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Nonresident Wholesaler (OSD)	Active[1]	802	805		
	Out of State	802	805		
	Out of Country	N/A	N/A		
	Delinquent/Expired	45	47		
	Retired Status if applicable	N/A	N/A		
	Inactive	N/A	N/A		
	Other[2]	0	0		

Total Licensees			
FY 2024/25	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
139,445	139,270		

The Board publicly reports its performance at quarterly Board meetings. In addition, the Board submits to DCA to publish its Licensing Performance Measures (LPM) data every quarter This data shows how long it takes, on average, to process different types of license applications – whether complete, incomplete, or renewal – helping applicants and the public better understand licensing timelines.

The Board established extremely aggressive performance targets that balance the Board's mandate to protect consumers with the needs of individuals and businesses entering the marketplace.

The Board's performance targets are provided below.

Board of Pharmacy Licensing Performance Measures Target Dates			
License Type	***Application Type***	***Status***	***Target (In Days)****
Advanced Pharmacist Practitioner	Advanced Pharmacist Practitioner Application	Complete	30
Automated Patient Dispensing System 340B Clinic	Automated Patient Dispensing System 340B Clinic Application	Complete	30
Centralized Hospital Packaging	Centralized Hospital Packaging Pharmacy License Application	Complete	45
Clinic	Clinic Permit Application	Complete	30
Designated Paramedic	Application for Designated Paramedic License	Complete	30

DRAFT

Board of Pharmacy Licensing Performance Measures Target Dates			
License Type	*Application Type*	*Status*	*Target (In Days)**
Designated Representative – Reverse Distributor	Application for a Designated Representative Reverse Distributor License	Complete	30
Designated Representative – Wholesaler	Application for a Designated Representative License	Complete	30
Designated Representative – 3PL	Application for Designated Representative – 3PL	Complete	30
Designated Representative – Veterinary Food-Animal Drug Retailer	Designated Representative – Veterinary Food-Animal Drug Retailer Application	Complete	30
Exempt Hospital (Drug Room)	Drug Room Application	Complete	30
Hospital Pharmacy	Hospital Pharmacy Permit Application	Complete	30
Hospital Satellite Compounding	Hospital Satellite Sterile Compounding License	Complete	45
Hypodermic Needle and Syringe	Application for Hypodermic Needle and Syringe Permit	Complete	30
Intern Pharmacist	Application for Registration as an Intern Pharmacist	Complete	15
Licensed Correctional Pharmacy	Licensed Correctional Pharmacy	Complete	30
Outsourcing Facility	Outsourcing Facility Application	Complete	45
Outsourcing Facility – Nonresident	Outsourcing Facility- Nonresident Application	Complete	45
Pharmacist	Application for Pharmacist Examination and Licensure	Complete	15
	Application for Pharmacist Initial License	Complete	5
Pharmacy	Pharmacy Permit Application	Complete	30
Pharmacy - Nonresident	Nonresident Pharmacy Permit Application	Complete	30
Pharmacy Technician	Pharmacy Technician Application	Complete	30
Sterile Compounding Pharmacy	Application for a Sterile Compounding Pharmacy License	Complete	45

DRAFT

Board of Pharmacy Licensing Performance Measures Target Dates			
License Type	*Application Type*	*Status*	*Target (In Days)**
Sterile Compounding Pharmacy - Nonresident	Application for a Nonresident Pharmacy Sterile Compounding License	Complete	45
Surplus Medication Collection and Distribution Intermediary	Application for Surplus Medication Collection and Distribution Intermediary License	Complete	45
Third-Party Logistics Provider	Application for Third-Party Logistics Provider License	Complete	30
Third-Party Logistics Provider – Nonresident	Application for Nonresident Third-Party Logistics Provider License	Complete	30
Veterinary Food-Animal Drug Retailer	Veterinary Food-Animal Drug Retailer Application	Complete	30
Wholesaler	Application for Wholesaler License	Complete	30
Wholesaler - Nonresident	Application for Nonresident Wholesaler License	Complete	30

FY 24/25	License Type	Application Type	Received	Approved/ Issued	Closed (Withdrawn)	Pending Applications Total (Close of FY)	# Complete-within Board control*	# Incomplete-outside Board control*
FY 2024/25	Advanced Pharmacist Practitioner (APH)	License	161	164	3	85	59	105
		Renewal	N/A	657	N/A	N/A	628	29
	Designated Paramedic (DPM)	License	0	0	0	0	0	0
		Renewal	N/A	21	N/A	N/A	20	1
		License	520	489	83	165	260	229

FY 24/25	License Type	Application Type	Received	Approved/ Issued	Closed (Withdrawn)	Pending Applications Total (Close of FY)	# Complete-within Board control*	# Incomplete-outside Board control*
	Designated Representative Wholesaler (EXC)	Renewal	N/A	2,407	N/A	N/A	2,373	34
	Designated Representative VET (EXV)	License	2	2	2	2	2	0
		Renewal	N/A	55	N/A	N/A	55	0
	Designated Representative 3PL (DRL)	License	137	143	100	57	87	56
		Renewal	N/A	459	N/A	N/A	457	2
	Designated Representative Reverse Distributor (DRR)	License	9	10	0	3	2	8
		Renewal	N/A	14	N/A	N/A	12	2
	Intern Pharmacist (INT)	License	1,260	1,251	19	46	1,017	234
		Renewal	N/A	N/A	N/A	N/A	N/A	N/A
	Pharmacist (RPH)	Examination	2,910	1436	4	1,601	1097	339
		License	1,357	1,358	0	0	1,334	24
		Renewal	N/A	22,742	N/A	N/A	22,122	620
	Pharmacy Technician (TCH)	License	6,237	5,802	141	2,118	3,691	2,111
		Renewal	N/A	28,766	N/A	N/A	25,980	2,786

FY 24/25	License Type	Application Type	Received	Approved/ Issued	Closed (Withdrawn)	Pending Applications Total (Close of FY)	# Complete-within Board control*	# Incomplete-outside Board control*
	Automated Drug Delivery System (ADD)	License	200	194	13	38	0	194
		Renewal	N/A	1,084	N/A	N/A	1,074	10
	Automated Drug Delivery System EMS (ADE)	License	0	0	0	0	0	0
		Renewal	N/A	0	N/A	N/A	0	0
	Automated Patient Dispensing System 340B Clinic (ADC)	License	6	2	0	0	0	2
		Renewal	N/A	3	N/A	N/A	3	0
	Centralized Hospital Packaging (CHP/CHE)	License	1	0	0	2	0	0
		Renewal	N/A	12	N/A	N/A	0	12
	Clinic (CLN/CLE)	License	216	164	49	206	21	143
		Renewal	N/A	2,247	N/A	N/A	2,078	169
	Exempt Hospital (Drug Room) (DRM/DRE)	License	0	0	0	1	0	0
		Renewal	N/A	30	N/A	N/A	29	1
	Hospital Pharmacy (HSP/HPE)	License	15	18	3	8	1	17
		Renewal	N/A	468	N/A	N/A	399	69
	Hospital Satellite Compounding Pharmacy (SCP/SCE)	License	2	0	1	4	0	0
		Renewal	N/A	10	N/A	N/A	0	10
	Hypodermic Needle and	License	12	3	8	30	0	3

DRAFT

FY 24/25	License Type	Application Type	Received	Approved/ Issued	Closed (Withdrawn)	Pending Applications Total (Close of FY)	# Complete-within Board control*	# Incomplete-outside Board control*
	Syringe (HYP/HYE)	Renewal	N/A	195	N/A	N/A	172	23
	Licensed Correctional Facility (LCF)	License	1	0	0	2	0	0
		Renewal	N/A	54	N/A	N/A	53	1
	Outsourcing Facility (OSF)	License	3	1	0	2	0	1
		Renewal	N/A	2	N/A	N/A	0	2
	Nonresident Outsourcing Facility (NSF)	License	9	3	6	10		
		Renewal	N/A	18	N/A	N/A	0	18
	Pharmacy (PHY/PHE)	License	1,265	751	414	704	124	627
		Renewal	N/A	5,561	N/A	N/A	5,329	232
	Nonresident Pharmacy (NRP)	License	137	110	22	196	25	85
		Renewal	N/A	510	N/A	N/A	253	257
	Remote Dispensing Pharmacy (PHR)	License	1	0	4	1	0	0
		Renewal	N/A	3	N/A	N/A	3	0
	Sterile Compounding Pharmacy (LSC/LSE)	License	70	73	21	44	0	73
		Renewal	N/A	829	N/A	N/A	0	829
	Nonresident Sterile Compounding Pharmacy (NSC)	License	20	14	6	19	1	13
		Renewal	N/A	44	N/A	N/A	0	44

FY 24/25	License Type	Application Type	Received	Approved/ Issued	Closed (Withdrawn)	Pending Applications Total (Close of FY)	# Complete-within Board control*	# Incomplete-outside Board control*
	Surplus Medication Distribution Intermediary (SME)	License	0	0	0	0	0	0
		Renewal	N/A	1	N/A	N/A	1	0
	Third-Party Logistics Provider (TPL)	License	5	7	0	8	0	7
		Renewal	N/A	34	N/A	N/A	29	5
	Nonresident Third-Party Logistics Provider (NPL)	License	36	36	34	39	0	36
		Renewal	N/A	146	N/A	N/A	136	10
	Veterinary Food-Animal Drug Retailer (VET)	License	0	0	1	0	0	0
		Renewal	N/A	16	N/A	N/A	15	1
	Wholesaler (WLS/WLE)	License	52	50	36	44	3	47
		Renewal	N/A	380	N/A	N/A	345	35
	Nonresident Wholesaler (OSD)	License	149	127	76	108	4	123
		Renewal	N/A	724	N/A	N/A	636	88

DRAFT

FY 25/26	License Type	Application Type	Received	Approved/ Issued	Closed (Withdrawn)	Pending Applications Total (Close of FY)	# Complete-within Board control*	# Incomplete-outside Board control*
FY 2025/26	Advanced Pharmacist Practitioner (APH)	License	198	139	51	94	54	85
		Renewal	N/A	713	N/A	N/A	696	17
	Designated Paramedic (DPM)	License	1	1	0	0	1	0
		Renewal	N/A	2	N/A	N/A	2	0
	Designated Representative Wholesaler (EXC)	License	418	327	15	239	156	171
		Renewal	N/A	2,583	N/A	N/A	2,567	16
	Designated Representative VET (EXV)	License	7	3	1	5	1	2
		Renewal	N/A	57	N/A	N/A	56	1
	Designated Representative 3PL (DRL)	License	130	103	1	82	52	51
		Renewal	N/A	537	N/A	N/A	534	3
	Designated Representative Reverse Distributor (DRR)	License	5	4	0	4	0	4
		Renewal	N/A	18	N/A	N/A	18	0
	Intern Pharmacist (INT)	License	1,350	1,287	4	112	1,045	242
		Renewal	N/A	N/A	N/A	N/A	NA	N/A

DRAFT

FY 25/26	License Type	Application Type	Received	Approved/ Issued	Closed (Withdrawn)	Pending Applications Total (Close of FY)	# Complete-within Board control*	# Incomplete-outside Board control*
	Pharmacist (RPH)	Examination	3,171	2418	4	1,775	1583	835
		License	1,629	1,584	0	0	1,539	45
		Renewal	N/A	23,392	N/A	N/A	22,885	507
	Pharmacy Technician (TCH)	License	6,383	5,004	443	2,967	3,565	1,439
		Renewal	N/A	28,022	N/A	N/A	26,728	1,294
	Automated Drug Delivery System (ADD)	License	382	274	16	110	0	274
		Renewal	N/A	1,061	N/A	N/A	604	457
	Automated Drug Delivery System EMS (ADE)	License	1	0	0	1	0	0
		Renewal	N/A	0	N/A	N/A	0	0
	Automated Patient Dispensing System 340B Clinic (ADC)	License	0	0	0	0	0	0
		Renewal	N/A	1	N/A	N/A	1	0
	Centralized Hospital Packaging (CHP/CHE)	License	2	0	0	2	0	0
		Renewal	N/A	9	N/A	N/A	0	9
	Clinic (CLN/CLE)	License	177	175	13	197	20	155
		Renewal	N/A	2,273	N/A	N/A	1,956	317
	Exempt Hospital	License	0	0	1	0	0	0

DRA

FY 25/26	License Type	Application Type	Received	Approved/ Issued	Closed (Withdrawn)	Pending Applications Total (Close of FY)	# Complete-within Board control*	# Incomplete-outside Board control*
	(Drug Room) (DRM/DRE)	Renewal	N/A	28	N/A	N/A	20	8
	Hospital Pharmacy (HSP/HPE)	License	19	17	0	9	0	17
		Renewal	N/A	472	N/A	N/A	390	82
	Satellite Sterile Compounding Pharmacy (SCP/SCE)	License	55	2	1	4	0	2
		Renewal	N/A	10	N/A	N/A	0	10
	Hypodermic Needle and Syringe (HYP/HYE)	License	6	3	4	29	0	3
		Renewal	N/A	207	N/A	N/A	170	37
	Licensed Correctional Facility (LCF)	License	0	0	1	1	0	0
		Renewal	N/A	54	N/A	N/A	47	7
	Outsourcing Facility (OSF)	License	2	1	0	2	0	1
		Renewal	N/A	3	N/A	N/A	0	3
	Outsourcing Facility-Nonresident (NSF)	License	8	1	4	11	0	1
		Renewal	N/A	19	N/A	N/A	1	18
	Pharmacy (PHY/PHE)	License	354	817	70	161	32	785
		Renewal	N/A	5,104	N/A	N/A	4,863	241
	Nonresident Pharmacy (NRP)	License	122	112	100	105	11	101
		Renewal	N/A	514	N/A	N/A	275	239

DRAFT

FY 25/26	License Type	Application Type	Received	Approved/ Issued	Closed (Withdrawn)	Pending Applications Total (Close of FY)	# Complete-within Board control*	# Incomplete-outside Board control*
	Remote Dispensing Pharmacy (PHR)	License	0	0	1	0	0	0
		Renewal	N/A	3	N/A	N/A	2	1
	Sterile Compounding Pharmacy (LSC/LSE)	License	55	58	3	39	0	58
		Renewal	N/A	766	N/A	N/A	4	762
	Nonresident Sterile Compounding Pharmacy (NSC)	License	17	14	1	23	0	14
		Renewal	N/A	46	N/A	N/A	2	44
	Surplus Medication Distribution Intermediary (SME)	License	0	0	0	0	0	0
		Renewal	N/A	1	N/A	N/A	1	0
	Third-Party Logistics Provider (TPL)	License	11	5	2	12	0	5
		Renewal	N/A	33	N/A	N/A	26	7
	Nonresident Third-Party Logistics Provider (NPL)	License	58	32	12	54	1	31
		Renewal	N/A	157	N/A	N/A	137	20
	Veterinary Food-Animal Drug Retailer (VET)	License	1	0	0	1	0	0
		Renewal	N/A	16	N/A	N/A	15	1
	Wholesaler (WLS/WLE)	License	54	24	18	50	0	24
		Renewal	N/A	389	N/A	N/A	328	61

DRAFT

FY 25/26	License Type	Application Type	Received	Approved/ Issued	Closed (Withdrawn)	Pending Applications Total (Close of FY)	# Complete-within Board control*	# Incomplete-outside Board control*
	Nonresident Wholesaler (OSD)	License	149	85	20	151	1	84
		Renewal	N/A	738	N/A	N/A	613	125

Average Time to Process Applications, Administer Exams and/or Issue License
Summary licensing information reveals the Board has realized a 20 percent increase in the overall number of applications received since fiscal year 2023/24 from the prior Sunset Report.

Licenses or Registrations Denied Based on Criminal History
Over the last two years the Board received 30,404 applications. The Board issued 20,862 licenses and denied 122 applications. The causes for denial vary based on the type of application. For example, an outsourcing facility may be denied if the facility fails to comply with current good manufacturing practices, while a pharmacist technician application may be denied due to a conviction the Board has determined to be substantially related to the duties of the profession.

DRAFT

Table 7b. License Denial				
	FY 2024/25	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
License Applications Denied without an appeal	27	53		
Statement of Issues Filed	21	20		
Average Days to File Statement of Issues	132	116		
Statement of Issues Declined	0	0		
Statement of Issues Withdrawn	3	1		
Statement of Issues Dismissed	1	0		
License Issued with Probation	2	4		
Average Days: Statement of Issued Filed to Outcome	214	281		

Application Denials

	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Criminal Conviction	33	57		
Total Denial	48	74		

Criminal Convictions

If an applicant had a conviction in more than one category, both are criminal convictions are reflected in the data. The data represents criminal convictions for all individual licensure applications.

	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Acts Involving Drugs/Alcohol	24	43		
Acts Involving Theft/Fraud	6	5		
Criminal Sexual Behavior	1	3		

DRAFT

	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Violent Crime	8	14		

Provided below is a summary of licensure applications that the Board denied:

FY 2024/25

- Pharmacy Technician: The Board denied 33 pharmacy technician applications, typically for one or more convictions of a crime substantially related to the functions of a pharmacy technician, including driving under the influence of alcohol, fraud, theft/embezzlement/burglary, violent acts, and previous discipline.

- Nonresident Outsourcing Facility: The Board denied three (3) nonresident outsourcing facility applications and one (1) nonresident outsourcing facility renewal application, primarily for failure to comply with current good manufacturing practices adopted by the Board.

- Pharmacy: The Board denied three (3) community pharmacy license applications based on failure to meet statutory requirements, including a corporation not legally authorized to operate in California, undisclosed ownership interests, and prior disciplinary history.

- Intern Pharmacist: The Board denied two (2) intern pharmacist application based on criminal history substantially related to the functions of an intern pharmacist, including acts involving drugs and alcohol and out-of-state discipline.

- Outsourcing Facility: The Board denied one (1) outsourcing facility renewal application and one (1) outsourcing facility application primarily for failure to comply with current good manufacturing practices adopted by the Board.

- Pharmacist: The Board denied one (1) pharmacist application based on prior license discipline.

- Advanced Pharmacist Practitioner (formerly known as Advanced Practice Pharmacist): The Board denied one (1) advanced pharmacist practitioner license based on a pending Board investigation.

- Wholesaler: The Board denied one (1) wholesaler application based on unprofessional conduct, prohibited acts related to dangerous drugs and devices, maintenance of records, security and storage conditions.

- Nonresident Sterile Compounding Pharmacy: The Board denied one (1) nonresident sterile compounding pharmacy renewal application, primarily for failure to notify the Board of an adverse reaction, false statements, and non-compliance with United States Pharmacopeia (USP 797) compounding standards.

DRAFT

FY 2025/26

- Pharmacy Technician: The Board denied 53 pharmacy technician applications, typically for one or more convictions of a crime substantially related to the functions of a pharmacy technician, including driving under the influence of alcohol and or drugs, possession of controlled substances, theft/shoplifting, violent acts, previous discipline. Additionally, two (2) pharmacy technician applications were denied as a result of a mental evaluation pursuant to California Code of Regulations section 1769.

- Designated Representative: The Board denied seven (7) designated representative applications based on criminal history substantially related to the functions of designated representative, including acts involving alcohol, violent crimes, and unprofessional conduct.

- Pharmacy: The Board denied six (6) community pharmacy license applications based on failure to meet statutory requirements, including a corporation not legally authorized to operate in California, undisclosed ownership interests, false statements, prior disciplinary history, and pending Board investigations.

- Nonresident pharmacy/sterile compounding: The Board denied one (1) nonresident pharmacy application and one (1) nonresident sterile compounding pharmacy license primarily for failure to comply with current good manufacturing practices adopted by the Board.

- Intern Pharmacist: The Board denied one (1) intern pharmacist application based on unprofessional conduct.

- Outsourcing Facility: The Board denied one (1) outsourcing facility renewal application primarily for failure to comply with current good manufacturing practices adopted by the Board.

- Wholesaler: The Board denied one (1) wholesaler application based on unprofessional conduct and providing false/misleading information.

- Nonresident Wholesaler: The Board denied one (1) nonresident wholesaler application based on failure to meet statutory requirements, including a corporation not legally authorized to operate in California.

Verification of Information from Applicants

Application Information

The Board uses multiple processes to confirm information about an applicant to determine eligibility for licensure. Applicants are required to submit their fingerprints to the California Department of Justice (DOJ) for DOJ to conduct a Criminal Offender Record Identification (CORI) search through the DOJ and the Federal Buruea of Investigations (FBI) database. The Board initially established this requirement with pharmacists to comply with submitting their

DRAFT

fingerprints since the 1940s. The Board requires all individuals applying for a personal license to comply with the CORI search through the DOJ and FBI.

In addition, the Board requires owners, individuals with management and control and designated managers for site license applications depending on the ownership structures and legal requirements to comply with the CORI search through the DOJ and FBI database.

In addition, these individuals are required to report under oath conviction(s) and any previous or close association to anyone disciplined by any regulatory agency.

Applicants who self-report a criminal conviction or prior discipline by a regulatory agency are requested to submit documentation describing the action and resolution. The Board investigates and considers information from a variety of sources, including information and mitigation provided by applicants before making a licensing decision.

The Board maintains secure access to the National Association of Boards of Pharmacy (NABP) to verify applicants' pharmacy degree completion, educational requirements, and licensure status in other jurisdictions. The Board also accepts official electronic transcripts submitted through Parchment and the National Student Clearinghouse. For foreign educated applicants, staff use NABP resources to confirm educational credentials. Additionally, the Board obtains reports from the National Practitioner Data Bank to review and assess any disciplinary actions issued by other regulatory agencies and staff conducts license verification reviews on other regulatory agency websites to confirm licensure status.

Staff conduct online license verifications for licensees who hold or held a license in another state or with the California Department of Public Health and verify business' Statement of Information filed with the California Secretary of State for site applications. In addition, the Board verifies licenses through the DCA's licensure system to confirm licensure for individuals licensed by other regulatory Boards.

For applications that require certifications, staff will verify the certification from the appropriate organization depending on the application and requirements in addition to reviewing supporting documents received as part of the application process to confirm accuracy. When necessary, the Board will conduct a search in Lexus Nexus to confirm or verify ownership information.

Out-of-State/Out-of-Country Applications

The Board requires out-of-state pharmacist applicants to meet the same examination and licensure requirements as California graduates. Foreign-educated pharmacists are required to be certified by the Foreign Pharmacy Graduate Examination Committee (FPGEC) as a qualification for issuance of an intern pharmacist license or meeting the pharmacists

DRAFT

educational requirements to be made eligible to sit for the pharmacist licensure exams as defined in Bus. Prof. Code §§ sections 4200 and 4208.

Out-of-state businesses must also meet all of the same licensure requirements as California businesses. In addition to application materials, the Board requires state license verification as well as a copy of the most recent inspection report conducted by a regulatory or licensing agency of the state where the business is located for many nonresident license programs. This information assists the Board in conducting a background check before issuing a California license to an out-of-state business. Effective July 1, 2026, Bus. Prof. Code §§ 4112, 4113, and 4113.1 were amended, providing the Board with the authority for to inspect a nonresident pharmacy and assess a reasonable fee to cover the Board's costs. In addition, the provisions require a nonresident pharmacy to designate a California-licensed pharmacist to serve as the pharmacist-in-charge (PIC). As the Board continues its implementation efforts in this area, approximately 64% of nonresident pharmacies have complied with the requirement to have a California-licensed pharmacist to serve as the PIC. Board staff continue to focus on securing compliance through education.

Military Education and Training

With the exception of the intern pharmacist license (which does not have an experience component as a pathway to licensure), the Board accepts military training and experience for purposes of licensure. Further, the pharmacy technician requirements for licensure specifically establish training earned in the military as one pathway to licensure.

Over the past two fiscal years the Board has waived renewal fees and continuing education requirements for 10 individuals in fiscal year 25/26 pursuant to BPC section 114.3. This has not caused an impact on revenues.

Over the past two fiscal years the Board has expedited the processing of the following military applications.

Military Expedite Applications	FY 24/25	FY 25/26	FY 26/27	FY 27/28
Military Spouse/Partner. BPC 115.5	9	13		
Serving in the Military, BPC 114.5	5	10		
Veterans, BPC 115.4	85	2		
Military SkillBridge Program BPC 115.4	0	0		
Total	99	25		

Over the past two fiscal years the Board has expedited the following applications for refugees for the following:

Refugee Expedite Applications	FY 24/25	FY 25/26	FY 26/27	FY 27/28
Refugee pursuant to section 1157 of Title 8 of the United States Code	6	0		
Refugee granted asylum by the Secretary of Homeland Security or the Attorney General of the United States pursuant to section 1158 of Title 8 of the United States Code.	17	4		
Refugee with a special immigrant visa that has been granted a status pursuant to section 1244 of Public Law 110-181, Public Law 109-163, or section 602(b) of title VI of division F of Public Law 111-8.	6	0		
Total	29	4		

Over the past two fiscal years, the Board has issued temporary individual license to military spouse or partner pursuant to BPC section 115.6.

Temporary Licenses Issued	FY 24/25	FY 25/26	FY 26/27	FY 27/28
Military Spouse/Partner. BPC 115.6	7	9		

In addition, the Federal Servicemembers Civil Relief Act (SCRA) has authorized service members or their spouses who currently hold a valid license in good standing in another state, district, or territory to practice in California within the same profession or vocation, if they relocate to California because of military orders.

Federal Servicemembers Civil Relief Act (SCRA)	FY 24/25	FY 25/26	FY 26/27	FY 27/28
Service Members or their Spouses Authorized to Practice in California	7	9		

No Longer Interested Notifications

As a condition of licensure, applicants and/or licensees are required to submit their fingerprints to the California Department of Justice (DOJ) for DOJ to conduct a Criminal Offender Record Identification (CORI) search through the DOJ and the Federal Buruea of Investigations (FBI) database. The Board is required to notify DOJ when the Board is no longer interested in obtaining subsequent arrest notifications for individuals whose application or license is cancelled, revoked, surrendered, denied, or withdrawn.

The Board with DCA's Office of Information Services, implemented an automated monthly process to submit "No Longer Interested" (NLI) notifications when the Board no longer has authority to receive the CORI information from DOJ.

In addition to the automated process, the Board continues to manually submit to DOJNLI notifications at the time of identifying when the Board no longer has the authority to receive the CORI information from DOJ, such as for the reasons listed above.

	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
No Longer Interested Notifications Submitted to DOJ	881	1,068		

Examinations Required for Licensure

Applicants for licensure as a pharmacist must take and pass both the North American Pharmacist Licensure Examination (NAPLEX) and the California Practice Standards and Jurisprudence Examination for Pharmacists (CPJE). The National Association of Boards of Pharmacy (NABP) develops the NAPLEX exam which is the national examination for licensure as a pharmacist used by all states. By statute, the CPJE exam is developed by the Board to assess California-specific law applications, patient consultation skills and other areas of California pharmacy practice not tested by the NAPLEX. Both exams are offered in English only.

Pass Rates for First Time vs. Retakes

Twice a year the Board publishes passing rate information for both the CPJE as well as the NAPLEX for California applicants who have taken both exams. Table 8 Examination Data is a comprehensive report detailing exam performance for the past four fiscal years.

Table 8(a). California Practice Standards and Jurisprudence Examination for Pharmacists (CPJE)				
CPJE	**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Number of Candidates	1,669	3,249		
Overall Pass %	61%	49.98%		
Overall Fail %	39%	50.02%		

Date of last Occupational Analysis (OA) was October 2021. PSI Exams develops the OA for the Board. Next OA is targeted for January 2027.

Table 8(b). North American Pharmacy Licensure Examination (NAPLEX)				
NAPLEX	**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Number of Candidates	12,751	14,597		
Overall Pass %	75%	80.43%		
Overall Fail %	25%	19.57%		

Date of last Occupational Analysis (OA) was May of 2025. NABP develops the OA for the NAPLEX.

DRAFT

Computer-Based Testing

The NAPLEX and CPJE are administered via computer-based testing, available at testing locations nationwide and on a continuous basis. Upon approval of an application, an applicant receives a letter from the Board confirming eligibility to take the examination(s). It is the applicant's responsibility to schedule the exam through the appropriate vendor (PSI or Pearson VUE). The Board has strict standards for admittance into the testing area as well as security procedures in use during test administration for the CPJE.

NAPLEX

The NAPLEX is administered through a different contractor secured by the NABP, Pearson VUE. The NAPLEX is administered in all 50 United States, US territories, and the District of Columbia, with 27 test sites in California.

CPJE

Computer based testing provides an easy and convenient way for candidates to take the CPJE. However, even with tight security at examination sites, such testing is not without risk of subversion.

The Board's secured vendor PSI Services Inc is part of DCA's department-wide contract to administer the CPJE via computer-based testing Candidates are able to schedule for the CPJE by either contacting PSI directly or through PSI's online portal after the Board notifies them of their eligibility to sit for the CPJE.

Candidates for the CPJE may select from 20 testing sites in California and 22 testing outside of California.
California: Agoura Hills, Atascadero, Bakersfield, Carson, Diamond Bar, El Monte, Fresno, Irvine, Lawndale, Redding, Riverside, Sacramento, San Diego, San Francisco, Santa Clara, Santa Rosa, Union City, Ventura, Visalia, and Walnut Creek.
Outside of California: Albuquerque, NM; Atlanta, GA; Bronx, NY; Centennial, CO; Charlotte, NC; Cherry Hill, NJ; Chicago, IL; Dallas, TX; Houston, TX; Milford, CT; Nashville, TN; Olathe, KS; Philadelphia, PA; Richmond, VA; Southfield (Detroit Area), MI; Springfield, MA; Tulsa, OK; Vancouver, WA; West Des Moines, IA; West Hartford, CT; Wilsonville, OR; and Wheatridge, CO.

For Fiscal Years 2024-25 through 2025-26, the Board offered 12-13 days to test each year. The days of testing are strategically selected to accommodate the highest number of candidates throughout the year. Factors considered include, but are not limited to, graduation dates of candidates, accommodation on weekdays and weekends, avoidance of religious holidays, the ability for candidates to retake the CPJE 45 days after a failed attempt; and feedback the Board received from residency programs.

Occupational Analysis

The Board is required to ensure the contemporary standards of practice for pharmacists in California are assessed through the CPJE as defined in Bus. Prof. Code §4200.2(b) as the

DRAFT

standards are not included on the North American Pharmacy Licensure Examination (NAPLEX).

The Board has initiated the 2026 occupational analysis review for the CPJE. To complete this process, the Board must obtain the results of the National Association of Boards of Pharmacy's (NABP) occupational analysis of the NAPLEX. These results are required to evaluate NAPLEX's updated detailed content outline and compare it with the CPJE's updated outline, ensuring compliance with Business and Professions Code section 4200.2(b).

The Board has completed the occupational analysis of the CPJE and anticipates the new CPJE detailed content outline will be implemented in 2027. The NABP's updated occupational analysis for the NAPLEX took effect on May 1, 2025.

Statutes that Hinder Processing of Applications/Examinations

Processing times are hindered by the Board's reliance on paper versus challenges with statutory requirements. When barriers to licensure are identified, the Board pursues statutory changes to resolve the issues. The Board identified through implementing statutory amendments to Business and Professions Code 4200.5 related to retired pharmacist license, Assembly Bill (AB) 1503 while it updated the provisions for a retired pharmacist license, establishing an alternative pathway for restoration of a retired pharmacist license within three years of issuance of the retired license it did not include provisions to issue a retired advanced pharmacist practitioner license. At the January 26-27, 2026 Board meeting the Board agreed to sponsor a legislative change to add section 4212 to establish provisions for a retired Advanced Pharmacist Practitioner (APH) license.

School Approvals

The Board does not approve schools of pharmacy. Instead, Pharmacy Law defines "recognized school of pharmacy" as a school of pharmacy accredited or granted candidate status by the Accreditation Council for Pharmacy Education (ACPE). The ACPE is the sole accrediting body for pharmacist education in the United States. The Board does not have an official role with the ACPE; however, a Board member attends and observes accrediting and reaccrediting visits at California schools of pharmacy.

Additionally, the Board receives updates from ACPE on changes in school accreditation status. The ACPE does not grant full accreditation status until a school graduates its first class of pharmacists, which generally takes four years. The Board has used its statutory authority to recognize schools of pharmacy for the limited purpose of issuing intern pharmacist licenses to applicants from schools on track to receive full accreditation by ACPE. The Board could remove its recognition of a school of pharmacy if necessary; however, this has never occurred.

There are currently 14 fully accredited pharmacy schools in California

- American University of Health Sciences School of Pharmacy, Signal Hill, CA
- California Northstate University College of Pharmacy, Elk Grove, CA
- Chapman University School of Pharmacy, Irvine, CA

DRAFT

- Keck Graduate Institute (KGI) School of Pharmacy and Health Sciences, Claremont, CA
- Loma Linda University School of Pharmacy, Loma Linda, CA
- Touro University – California College of Pharmacy, Vallejo, CA
- University of California, San Diego Skaggs School of Pharmaceutical Sciences, La Jolla, CA
- University of California, San Francisco School of Pharmacy, San Francisco, CA
- University of Southern California School of Pharmacy, Los Angeles, CA
- University of the Pacific Thomas J. Long School of Pharmacy and Health Sciences, Stockton, CA
- West Coast University School of Pharmacy, Los Angeles, CA
- Western University of Health Sciences College of Pharmacy, Pomona, CA
- Marshall B. Ketchum University College of Pharmacy, Fullerton, CA
- University of California, Irvine School of Pharmacy, Irvine, CA

The Board has no legal requirements regarding approval of international schools.

Continuing Education/Competency Requirements
Pharmacy technicians are required to complete at least one hour of continuing education (CE) regarding cultural competency, as defined in Business and Professions Code (BPC) section 4231(a), during the two years preceding the application for renewal. See BPC section 4202(d). This requirement became operative January 1, 2024 under AB 2194. Currently, there is no provision under pharmacy law allowing pharmacy technicians to seek an exemption from completion of the CE renewal requirement.

Pharmacists are required to complete 30 hours of CE during the two years preceding the application for renewal. At least two of the 30 hours of CE shall be completed by participation in a Board-provided CE course in Law and Ethics (California Code of Regulations (CCR), Title 16, sections 1732.5(a) and (b)). Additionally, at least one hour of CE shall be completed by participation in a CE course regarding cultural competency, as defined in BPC section 4231(a). Newly licensed pharmacists are exempt from completing CE during their first renewal period.

Advanced pharmacist practitioners are required to complete 10 hours of CE. The subject matter shall be in one or more areas of practice relevant to the licensee's clinical practice. Newly licensed advanced pharmacist practitioners are exempt from completing CE during their first renewal period.

Prior to statutory changes that transition pharmacist practice to a more robust standard of care practice model for specified patient-care services, pharmacists were also required to complete additional CE requirements to furnish specified types of medications.

Pharmacists who prescribe any Schedule II controlled substances (as defined in Health and Safety Code section 11055) shall complete at least 1.00 hour of the required CE hours by participating in a Board-approved CE course once every four years on the risks of addiction

DRAFT

associated with the use of Schedule II drugs, as required by section 4232.5 of the Business and Professions Code.

In accordance with CCR section 1732.6, pharmacists may seek exemption from the CE requirements for renewal on the grounds of emergency or hardship by applying to the Board in writing setting forth the reasons why such exemption should be granted. Exemptions may be granted for such reasons as illness or full-time enrollment in a health professional school.

Continuing Education (CE)			
Type	Frequency of Renewal	Number of CE Hours Required Each Cycle	Percentage of Licensees Audited
TCH	Two years	1.00	0%
RPH	Two years	30.00	0.79%
APH	Two years	10.00	1.04%

CE Verification

Licensees self-certify that they have completed the required mandatory continuing (CE) education at the time they renew their license. This attestation is signed and submitted under penalty of perjury. Licensees are not required to provide further verification of CE completion unless requested by Board

The Board accepts certificates of completion by providers that include a statement of credit, the name of the enrollee, name and number of the provider, title of the course, number of completed hours, date of completion, expiration date of the coursework, course number, if applicable and the name of the accrediting agency as verification of completing the required CE as defined for requirements of accredited providers in Cal. Code of Regs, title 16, §. 1732.1(c).

Although not required by law, many licensees electively utilize the National Association of Boards of Pharmacy's (NABP) *CPE Monitor* to keep track of completed CE. The Board accepts the a pharmacist's *CPE Monitor Transcripts.* NABP allows for an Accreditation Council for Pharmacy Education (ACPE) accredited course provider to directly upload a licensee's verification of completing their CE course to *NABP's CPE Monitor*.in addition, licensees may have the option to upload non-ACPE accredited CE to their account with the NABP *CPE Monitor*. The Board does not consider verification of CE hours from non-ACPE accredited course providers whether the information is uploaded to the licensees NABP CPE Monitor transcript or sent directly to the Board.

Completion of Board-provided CE course offerings via the Board's learning management system, *PharmEd*, are verified internally by Board staff.

Currently, the Board does not utilize DCA's cloud for CE verification purposes.

DRAFT

CE Audits

Auditing for Compliance

The Board randomly audits renewal applications to ensure licensees fulfill CE requirements. Pharmacists are required to retain CE completion certificates for four years. Pharmacists and advanced pharmacist practitioners selected for audit are notified in writing and must submit copies of CE completion certificates to the Board. The Board reviews all of the certificates provided to confirm compliance with legal requirements.

When an audit reveals a deficiency, the Board typically instructs the licensee to obtain the required CE units. The Board may issue a citation and fine for misrepresenting completion of CE on the renewal form. For pharmacists who do not comply, their licenses are converted from active to inactive status as authorized in statute. To reactivate a license, a pharmacist must pay the renewal fee, if applicable and submit satisfactory proof of completing 30 hours of CE. The Board currently has not audited pharmacy technician licensees.

Pharmacists

	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Audits Initiated	87	397		
Passed	50	213		
Failed	55	184		
CE Failure percentage	51%	46%		
Inactivated/No Response to Audit	6	36		

Advanced Pharmacist Practitioner

	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Audits Initiated	2	17		
Passed	2	13		
Failed	0	4		
CE Failure percentage	0%	24%		
Inactivated/No Response to Audit	0	0		

Accreditation Agencies

The following accreditation agencies are approved by the Board to provide continuing education as specified in Cal. Code Regs, title 16, §1732.05:

- The Accreditation Council for Pharmacy Education
- The California Pharmacists Association.

In addition, the Board accepts continuing education coursework which meets the standard of relevance to pharmacy practice and is approved by the Medical Board of California, the California Board of Podiatric Medicine, the California Board of Registered Nursing or the Dental Board of California shall.

DRAFT

The Board has not undertaken efforts to review or revise its CE policy for consideration to transition toward performance-based assessments of licensee's continuing competence.

Licensees may petition the Board to request approval of CE credit for specific coursework, which is not offered by an approved provider, but is relevant to the practice of pharmacy. The fee required for a licensee to request the Board to review a non-recognized provider course is $40.00 per hour of coursework.

The Board does not audit CE providers.

Table 8a. Continuing Education						
Type	**Frequency of Renewal**	**Number of CE Hours Required Each Cycle**	**Percentage of Licensees Audited FY 2024/25**	**Percentage of Licensees Audited FY 2025/26**	**Percentage of Licensees Audited FY 2026/27**	**Percentage of Licensees Audited FY 2027/28**
Pharmacist	2 years	30	0.17%	0.79%		
Advanced Pharmacist Practitioner	2 years	40	0.13%	1.04%		
Pharmacy Technicians	1 year	1	0%	0%		

Section 4 – Enforcement Program

Performance Measures: Intake Cycle Time
Intake cycle time measures the average number of days from receipt of a complaint to the point at which the case is either assigned for investigation or closed without investigation. The Board is currently averaging 16 days, which does not meet the established performance target of 10 days. This is in part related to a 25 percent increase in complaints received. The Board is meeting the 10-day statutory requirement to notify a complainant of receipt of their complaint. However, the Board is currently not meeting its performance standard of assigning a complaint or desk investigation or closing without assignment within the DCA's performance standard of intake cycle time. of case assignments. To improve timeliness and achieve the Department's 10-day performance standard of intake cycle time, the Board is implementing a process to review and assign both complaint and desk investigations on a weekly basis.

Performance Measure 2: Intake Cycle Time

Fiscal Year	FY 24/25	FY 25/26	FY 26/27	FY 27/28
Complaints Received	3,167	3,971		
Performance Measure	10	10		
Average Assignment	14	16		

Performance Measure 3 – Investigation Cycle Time

Investigation cycle time represents the average number of days from receipt of a case investigation to its closure for investigations that did not result in referral to the Attorney General for disciplinary action. The Board is currently not meeting its performance standard. To improve overall investigative timeliness and meet established performance goals, the Board is redirecting staff resources, when available, and is looking for opportunities to enhance workflow efficiency and reduce case aging.

Performance Measure 3: Investigation Cycle Time

Fiscal Year	FY 24/25	FY 25/26	FY 26/27	FY 27/28
Investigations Closed	2,430	2,613		
Performance Measure	210	210		
Average Closure	276	310		

Investigation Closed within Performance Standards – Percentage of Cases Completed within Performance Standard

In addition to the performance measures reported by DCA, the Board internally seeks to complete desk investigations within 90 days and field investigations within 120 days. Additional information about the Board's investigation performance is provided in the table below.

	Performance Standard *	FY 24/25	FY 25/26	FY 26/27	FY 27/28
Desk Investigations	90 days	54%	55%		
Field Investigation	120 days	44%	48%		
Total Investigation Time Including Supervisor's Review	180 days	42%	44%		

*The 90 and 120-day timeframes apply from date of initial assignment to initial submittal for report review. The 180-day timeframe applies from date of initial assignment to closure.

The data presented above illustrate that the Board is not currently meeting its established performance measures for investigative timeframes. In recent years, the Board has experienced a steady increase in both desk and field investigations. Delays in obtaining essential information from external sources continue to challenge the timely completion of

desk investigations, and the Board is evaluating potential statutory changes to the Pharmacy Law to help address these barriers.

The duration of field investigations vary significantly in complexity based on the nature and scope of each case. Additionally, the Board is prioritizing the resolution of its oldest cases, which can temporarily extend the processing time for more recently opened matters. As these older investigations are completed, the Board anticipates improvements in the percentage of field investigations closed within the performance standards. Similar improvements are expected in overall investigation cycle times as cases continue to move through the review process to final resolution.

Enforcement Trends: Investigations

The Board initiates investigations based on a variety of internal and external triggers. Over the past two years, the Board has seen an overall increase of approximately 26 percent in investigative activity.

Rising workload demands, combined with staffing constraints, continue to present operational challenges. In response, the Board conducted a comprehensive workload analysis and redirected internal resources to areas with the greatest need. The Enforcement Program is currently undergoing reorganization, and internal procedures are being reviewed and updated to improve efficiency. Recent streamlining efforts have also enhanced the Board's complaint processing workflow, resulting in more timely handling of consumer complaints.

Since fiscal year 2024/25, the number of cases referred for investigation increased by 38 percent. During this period, the Board received an increase in the number of complaints involving pharmacies and pharmacists declining to fill controlled substance prescriptions, as well as complaints against chain community pharmacies for difficulties in reaching staff due to unanswered calls or reliance on automated phone systems.

In fiscal year 2025/26, the Board experienced increased complaints involving telehealth companies, particularly regarding challenges in obtaining prescription medications and concerns about unlicensed companies selling peptides such as semaglutide or tirzepatide. The Board also experienced growth in consumer complaints related to vaccinations, which include consumer complaints regarding pharmacies outreach at the pharmacy counter and/or via phone/text recommending the patient receive vaccinations, complaints received by pharmacists indicating they are required to meet quotas related to vaccination administration, and isolated reports of the wrong vaccine being administered to the patient.

Additionally, over the past two years, the Board has observed a 58 percent increase in desk investigations. This growth is largely attributable to continuing education audit failures and criminal conviction related matters. The average time to close desk investigations has also risen by 58 percent, as the Board prioritizes resolving older cases.

The Board's recent emphasis on enhanced educational outreach to licensees and the implementation of more routine inspection oversight appears to have contributed to a 26

percent reduction in issued citations. However, total fine collections increased by 13 percent, a trend that aligns with the Board's authority to levy higher fines for certain entities, including chain community pharmacies, as well as its expanded authority to impose penalties for unlicensed activity.

Overall, the data demonstrates sustained increases in workload across complaint intake, investigations, and disciplinary processes, accompanied by longer processing times and continued staffing challenges. These trends reflect the Board's expanding enforcement responsibilities and the growing complexity investigations.

Table 9. Enforcement Statistics				
	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Complaints Received	2,873	3,630		
Complaints Closed without Referral for Investigation	632	541		
Complaints Referred to Investigation	2,228	3,070		
Complaints Pending at end of fiscal year	64	69		
Conviction / Arrest Received	512	560		
Conviction / Arrest Closed Without Referral for Investigation	42	21		
Conviction / Arrest Referred to Investigation	407	584		
Conviction / Arrest Pending at end of fiscal year	63	20		
***Source of Complaint* - Public**	1,731	2,248		
***Source of Complaint* - Licensee/Professional Groups**	490	525		
***Source of Complaint* Governmental Agencies**	391	475		
***Source of Complaint* - Internal**	561	680		
***Source of Complaint* - Other**	0	0		
***Source of Complaint* - Anonymous**	211	263		
Average Time to Refer for Investigation (from receipt of complaint / conviction to referral for investigation)	13.22	13.68		
Average Time to Closure (from receipt of complaint / conviction to closure at intake)	16.53	18.28		

Table 9. Enforcement Statistics				
	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Average Time at Intake (from receipt of complaint / conviction to closure or referral for investigation)	13.69	15.62		
***Desk Investigations* - Opened**	629	996		
***Desk Investigations* - Closed**	530	676		
***Desk Investigations* - Average days to close (from assignment to investigation closure)**	273.02	431.76		
***Desk Investigations* –Pending at end of fiscal year**	704	1,078		
***Non-Sworn Investigation* - Opened**	2,005	2,655		
***Non-Sworn Investigation* - Closed**	1,897	1,934		
***Non-Sworn Investigation* - Average days to close (from assignment to investigation closure)**	269.85	267.66		
***Non-Sworn Investigation* - Pending at end of fiscal year**	1,509	2,202		
Sworn Investigation - Opened	1	3		
Sworn Investigation - Closed	3	3		
Sworn Investigation - Average days to close (from assignment to investigation closure)	415.67	361.67		
Sworn Investigation - Pending at end of fiscal year	2	2		
***All investigations* - Opened**	2,635	3,654		
***All investigations* - Closed**	2,430	2,613		
***All investigations* - Average days for all investigation outcomes (from start investigation to investigation closure or referral for prosecution)**	270.72	310.22		
***All investigations* - Average days for investigation closures (from start investigation to investigation closure)**	262.54	296.39		
***All investigations* - Average days for investigation when referring for prosecution (from start investigation to referral for prosecution)**	386.12	474.33		

DRAFT

Table 9. Enforcement Statistics				
	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
***All investigations* - Average days from receipt of complaint to investigation closure**	275.50	310.21		
***All investigations* - Pending at end of fiscal year**	2,215	3,282		
Citations & Fine Issued	642	477		
Citations & Fine Issued - Average Days to Complete (from complaint receipt to citation issued)	430	491		
Citations & Fine Issued - Amount of Fines Assessed	$1,976,050	$1,114,150		
Citations & Fine Issued - Amount of Fines Reduced, Withdrawn, Dismissed	$889,141	$43,750		
Citations & Fine Issued - Amount Collected	$1,738,290	$1,958,092		
Criminal Action - Referred to Criminal Prosecution	N/A	N/A		
Accusations Filed	138	146		
Accusations Declined	0	0		
Accusations Withdrawn	7	7		
Accusations Dismissed	1	2		
Accusations - Average Days from Referral to Accusations Filed (from AG referral to Accusation filed)	182.41	210.23		
Interim Order – Interim Suspension Order (ISO) & (Temporary TRO Issued	16	8		
PC 23 Orders Issued	3	6		
Other Suspension/Restriction Orders Issued	2	1		
Referred for Diversion	2	2		
Petition to Compel Examination Ordered	24	18		
DISCIPLINE				
AG Cases Initiated (cases referred to the AG in that year)	131	188		
AG Cases Pending Pre-Accusation (close of FY)	214	199		
AG Cases Pending Post-Accusation at end of fiscal year	251	194		
DISCIPLINARY OUTCOMES				

DRAFT

Table 9. Enforcement Statistics				
	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Revocation	77	57		
Surrender	42	26		
Suspension only	0	0		
Probation with Suspension	0	0		
Probation only	74	46		
Public Reprimand / Public Reproval / Public Letter of Reprimand	34	20		
Other	6	1		
DISCIPLINARY ACTIONS				
Proposed Decision	17	7		
Default Decision	66	55		
Stipulations	117	70		
Average Days to Complete After Accusation (from Accusation filed to imposing formal discipline)	305.35	308.49		
Average Days from Closure of Investigation to Imposing Formal Discipline	447.83	470.10		
Average Days to Impose Discipline (from complaint receipt to imposing formal discipline)	845.44	895.19		
Probations Completed	104	85		
Probationers Pending at end of fiscal year	238	203		
Probationers Tolled	36	40		
Probationers Petitions to Revoke Probation / Accusation and Petition to Revoke Probation Filed	8	10		
Probationers Revoked	5	3		
Probationers' License Surrendered	3	2		
Subsequent Discipline Probationers-Extended Probation	1	5		
Subsequent Discipline-Probationer Suspension Added to Term	0	0		
Subsequent Discipline - Other Conditions Added Only	0	0		
Subsequent Discipline - Other Probation Outcome	0	0		
Subsequent Discipline - Other Outcomes	2	0		

Table 9. Enforcement Statistics				
	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Probationers Subject to Drug Testing	89	79		
Probationers - Drug Tests Ordered	771	930		
Probationers - Positive Drug Tests	0	6		
Petition for Termination or Modification Granted	14	5		
Petition for Termination or Modification Denied	5	7		
Petition for Reinstatement Granted	1	0		
Petition for Reinstatement Denied	2	0		
Pharmacist Recovery Program – Intakes	18	9		
Pharmacist Recovery Program – Successful Completions	7	5		
Pharmacist Recovery Program – Participants at end of fiscal year	30	27		
Pharmacist Recovery Program – Terminations/Close Non-Public Threat	5	3		
Pharmacist Recovery Program – Terminations for Public Threat	1	4		
Pharmacist Recovery Program – Drug Tests Ordered	1080	1157		
Pharmacist Recovery Program – Positive Drug Tests	2	3		

Table 10. Enforcement Aging						
Investigations (Average %) Closed Within:	**FY 2024/25**	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**	**Cases Closed**	**Average %**
90 Days	339	284				
91 - 180 Days	660	763				
181 - 1 Year	891	825				
1 - 2 Years	444	516				
2 - 3 Years	77	183				
Over 3 Years	19	42				
Total Investigation Cases Closed	2,430	2,613				
Attorney General Cases (Average %) Closed Within:						
0 - 1 Year	29	18				

DRAFT

1 - 2 Years	109	73				
2 - 3 Years	83	56				
3 - 4 Years	29	34				
Over 4 Years	12	9				
Total Attorney General Cases Closed	262	190				

The executive officer, or a designated representative, may determine that a violation is sufficiently egregious to warrant formal disciplinary action against a licensee. In such cases, the matter is referred to the Attorney General's Office for further evaluation. If deemed appropriate, the Attorney General will prepare an accusation or other legal pleading outlining the specific violations of pharmacy law. Potential disciplinary outcomes include interim suspension orders, license revocation, voluntary surrender of a license, suspension, letters of reprimand, and probation.

The number of cases referred to the Office of the Attorney General increased by about 70 percent during the reporting period. The Board notes the following most common violations referred for discipline.

Five Most Common Violations Included in Accusations

FY 2024/25

1. BPC 4301(f) - Moral Turpitude, Dishonesty, etc.
2. BPC 4301(l) - Related Crimes/Convictions
3. BPC 4301 - Unprofessional Conduct
4. BPC 4301(h)- Self-use of Dangerous Drugs/Alcohol
5. BPC 4301(j) - Controlled Substance and Dangerous Drug Violations

FY 2025/26

1. BPC 4301(f) - Moral Turpitude, Dishonesty, etc.
2. BPC 4301(l) - Related Crimes/Convictions
3. BPC 4301- Unprofessional Conduct
4. BPC 4301(h) - Self-use of Dangerous Drugs/Alcohol
5. BPC 4301(j) - Controlled Substance and Dangerous Drug Violation

Case Prioritization

The Board uses a case prioritization system tailored to meet the diversity of individual licensees and practice settings. Supervising inspectors establish priorities for field investigations. Complaints categorized as priority 1 and 2 are the most serious and pose the highest risk to public health and safety. Examples include reports of an impaired licensee on duty, prescription drug theft by a licensee, a pharmacy operating without a pharmacist on duty, controlled substances losses, sterile compounding violations, and unauthorized furnishing of prescription drugs and/or controlled drugs. Where violations are confirmed,

priority 1 and 2 complaints are generally referred to the Office of the Attorney General for formal disciplinary action. The Board pursues these cases vigorously and seeks an appropriate penalty through an administrative hearing or stipulated settlement.

Priority 3 and 4 complaints are less serious and pose a lower risk to the health and safety of the public. Examples include failure to provide patient consultation, prescription errors not involving patient harm, working with an expired license, and general noncompliance issues. Priority 3 and 4 complaints typically result in the issuance of a citation, a citation and fine, a letter of admonishment, or through education of the subject.

The Board believes its priorities are generally consistent with DCA's priorities; however, note some differences, including for example cases involving compounding violations.

Mandatory Reporting

State law establishes the following mandates for reports to the Board:

Business and Professions Code Section 801(a) – Requires every insurer who provides liability insurance to a Board of Pharmacy licensee to report to the Board any settlement or arbitration award over $3,000 in a claim or action for damages for death or personal injury caused by the licensee's negligence, error, or omission in practice or for unauthorized professional services. A report, written and signed by all parties, must be submitted to the Board within 30 days after service of the arbitration award on all parties.

Business and Professions Code Section 802 – Requires Board licensees or their legal representatives to report every settlement or arbitration award over $3,000 due to a "claim or action for damages for death or personal injury caused by negligence, error or omission in practice." The Board receives notification of these settlements from the insurance company settling the claim or from a licensee's counsel.

Business and Professions Code Section 803 –Requires the clerk of a court that renders a judgment that a licensee has committed a crime; or is liable for any death or personal injury resulting in a judgment for an amount over $30,000 caused by the licensee's negligence, error or omission in practice; or his or her rendering of unauthorized professional services, to report that judgment to the Board within 10 days after the judgment is entered.

Business and Professions Code Section 4104 (c) –Requires every pharmacy report to the Board within 14 days of the receipt or development of information that a licensed individual employed by or with the pharmacy has made or has received: (1) any admission by a licensed individual of chemical, mental, or physical impairment to the extent it affects his or her ability to practice pharmacy; or (2) any admission of theft, diversion, or self-use of dangerous drugs; or (3) any video or documentary evidence demonstrating chemical, mental, or physical impairment to the extent it affects his or her ability to practice pharmacy; or (4) any video or documentary evidence demonstrating theft, diversion, or self-use of dangerous drugs; or (5) any termination based on theft, diversion, or self-use of dangerous drugs.

DRAFT

Business and Professions Code Section 4126.9 – Requires notice to the Board within 12 hours of any recall notice issued by a pharmacy for a nonsterile compounded drug product.

Business and Professions Code Section 4127.1 – Requires notice to the Board within 12 hours of any recall notice issued by a pharmacy for sterile drug products it has compounded. Further, adverse effects reported or potentially attributable to a pharmacy's sterile drug products must also be reported to the Board.

Business and Professions Code Section 4129.9 – Requires notice to the Board within 24 hours of a recall notice under specified conditions.

Business and Professions Code Section 4169.1 – Requires a wholesaler to notify the Board of any suspicious orders of controlled substances placed by a California-licensed pharmacy or wholesaler.

Title 16, California Code of Regulations Section 1715.6 – Requires a facility owner to report to the Board within 30 days of the discovery of a loss of specified amounts of controlled a substance(s). The Board educates licensees about these mandatory reporting requirements through its newsletter and through public discussions. Further, some of the reporting requirements are also included in the Board's self-assessment forms.

The Board educates licensees about these mandatory reporting requirements through its newsletter and through public discussions. Further, some of the reporting requirements are also included in the Board's self-assessment forms.

Over the last two years, the Board has received 95 Section 800 reports, 68 reports of employee theft or impairment and approximately 27,826 (4,089) reports of drug losses. The Board is unable to track settlement amounts individually and notes that settlement amounts are sometimes confidential.

Settlements Entered with Licensees

The Board does not have authority to settle cases in advance of filing an accusation. The Board's Enforcement Committee and Board previously considered such a change, but ultimately determined it was not appropriate for the Board.

The number of cases, post-accusation, that were settled over the past two years is provided in the table below.

Post-Accusation Case Settlements

	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28	Total
Settlements	162	94			256
Hearing	34	23			57

The Board settles approximately 80 percent of its disciplinary cases.

The Board relies on the Office of the Attorney General (OAG) to provide legal representation in all disciplinary matters. The Board's policies governing disciplinary actions are outlined in its Disciplinary Guidelines (Guidelines), which categorize types of violations and establishes corresponding ranges of disciplinary outcomes. The Guidelines (Rev. April 2024) also detail standard and optional probation terms, expectations for rehabilitation, and factors the Board considers in mitigation or aggravation.

When working to resolve disciplinary matters prior to a hearing, Board staff and the OAG consult the Guidelines to identify case resolutions that align with the Board's consumer protection mandate. While each case presents unique circumstances, the Guidelines serve as a framework for understanding the Board's expectations regarding appropriate outcomes. If a settlement cannot be reached, the case proceeds to a formal administrative hearing.

Throughout the disciplinary process, respondents are encouraged to present mitigating information—either during settlement discussions or at a hearing—and bear the burden of demonstrating any rehabilitative or corrective steps they have undertaken.

Statute of Limitations
While the Board is not bound by a statute of limitations, it recognizes consumer protection as its highest priority and therefore strives to investigate each complaint as quickly as possible. In addition, the Board sets standards to monitor its performance.

Unlicensed Activity and the Underground Economy
The Board aggressively investigates unlicensed activity. The table below quantifies investigations involving allegations of unlicensed activity.

Unlicensed Activity Investigations

	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28	Total Indicated
Investigations	93	174			267

Examples of unlicensed activity include individuals or businesses operating without a license; unlicensed out-of-state operators providing services to Californians; and consumers buying drugs online from unlicensed vendors. The Board currently has the authority to issue a fine of up to $5,000 for unlicensed activity as well as the authority to issue a cease and desist. Regrettably, these actions do not serve as a sufficient deterrent to unlicensed activity. The Board is currently considering development of a proposal to increase the Board's fine authority for such violations.

Citation and Fine
The Board uses its authority to issue citations, citations with fines, and letters of admonition to deal with important violations that warrant correction but not license sanctions such as probation, suspension or revocation. The chart below shows the number of citations, citations and fines, and letters of admonishment that have been issued in the last two years.

DRAFT

Citation and Fines/Letters of Admonishment

Citation and Fines/Letters of Admonishment				
	FY 2024/25	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Letters of Admonishment	148	81		
Citations with No Fine	257	249		
Citations with Fine	385	227		
Fines Assessed	$1,976,050	$1,114,150		
Fines Collected	$1,738,289	$1,958,092		

The Board has statutory authority to issue citations, citations with fines, and letters of admonishment for violations of pharmacy law. Citations of up to $5,000 may be issued for:

- Any violation of the Pharmacy Law (Business and Professions Code section 4000 et seq.).
- Violations of regulations adopted by the Board.
- Violations of the Confidentiality of Medical Information Act (Civil Code section 56 et seq.).
- Defaulting on a United States Department of Health and Human Services education loan (limited to $2,500).
- Violations of any other statute or regulation for which the Board is authorized to issue a citation.

In most cases, the Board may issue fines of up to $5,000 to each licensee involved in a single investigation. This permits, for example, separate fines of up to $5,000 each for a pharmacy, a pharmacist, and a pharmacist-in-charge associated with the same violation. However, the Board exercises this authority conservatively and rarely issues the maximum fines to multiple respondents within the same case.

The Board assesses higher fines for more serious violations. The Pharmacy Law requires consideration of specific factors when determining fine amounts, including:

- The gravity of the violation.
- The cited person or entity's good or bad faith.
- History of previous violations.
- Evidence of whether the violation was willful.
- The level of cooperation with the Board's investigation.
- Efforts to mitigate damage or harm caused by the violation.
- The number of violations identified.
- Any other relevant circumstances.

Certain statutes authorize higher fines for specific conduct. For example, under Business and Professions Code section 4067, the Board may issue fines of $25,000 per prescription for internet drug sales conducted without an appropriate prior examination. In these cases, the pharmacy is deemed to be acting as a drug seller for an internet operator rather than practicing pharmacy.

DRAFT

The Board has the authority to issue fines of up to $5,000 per occurrence for designated violations. Business and Professions Code section 4126.5 authorizes fines of up to $5,000 per occurrence for furnishing dangerous drugs to unauthorized entities.

The Board has the authority to issue fines of up to $5,000 per occurrence for designated violations. Business and Professions Code section 4129.5 authorizes fines of up to $5,000 per occurrence for furnishing compounded sterile medication or nonsterile medication for nonpatient-specific distribution within or into California.

The Board has the authority to issue fines of up to $5,000 per occurrence for designated violations. Business and Professions Code section 4316.5 authorizes fines of up to $5,000 per occurrence for unlicensed activity.

Business and Professions Code section 4317.5(a), the Board may issue fines of up to $100,000 for repeated violations of materially similar provisions committed within five years by three or more pharmacies under common ownership or management within a chain community pharmacy. A third or subsequent violation may result in an administrative fine.

Business and Professions Code section 4317.5(b), the Board may pursue action against a chain community pharmacy under common ownership or management for fines up to $150,000 when a violation is demonstrated to result from a written policy or was expressly encouraged by the common owner or manager.

Business and Professions Code section 4317.6, effective January 1, 2026, the Board was given authority to bring an action for fines for repeated violations of materially similar provisions of this chapter within five years for a single mail order pharmacy, or multiple mail order pharmacies operating under common ownership or management for a third or subsequent violation, which may be punished by an administrative fine not to exceed one hundred thousand dollars ($100,000) per violation.

Appeal Process
Licensees who are issued a citation with or without a fine or a letter of admonishment may request an informal office conference. The office conference allows the licensee the opportunity to present additional or mitigating information to the Board's executive officer or designee and a supervising inspector. Upon conclusion, staff may affirm, modify, or dismiss the citation or affirm or dismiss the letter of admonishment.

In addition to an office conference, a licensee may submit a formal appeal to the Board within 30 days of the issuance of a citation. Appeals are conducted pursuant to the Administrative Procedure Act by an administrative law judge who renders a decision, which is presented to the Board for adoption or rejection. Letters of admonishment are not subject to the provisions of the Administrative Procedures Act.

	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Informal Office Conference	146	78		
Formal Appeal	50	90		

Five Most Common Violations for which Citations are Issued

2024/25

1. BPC 4301 - Unprofessional Conduct
2. CCR 1714 - Facilities Maintenance
3. CCR 1716 - Variation from Prescription
4. BPC 4113 - Notify Board of PIC Change
5. CCR 1761- Erroneous or Uncertain Prescriptions

2025/26

1. BPC 4301 - Unprofessional Conduct
2. CCR 1716 - Variation from Prescription
3. CCR 1714 - Facilities Maintenance
4. CCR 1715.65 - Controlled Substances Inventory Reconciliation
5. CCR 1761 - Erroneous or Uncertain Prescriptions

Average Fine Pre- and Post-Appeal

FY 2024/25	Number Appealed	Pre Appeal Average	Post Appeal Average
General Authority	34	$2,644	$1,868
BPC 4067	0	0	0
BPC 4126.5	0	0	0
BPC 4169	0	0	0
BPC 4317.5(a)	39	$12,654	$6,955
BPC 4317.5(b)	7	$72,143	$22,714

FY 2025/26	Number Appealed	Pre Appeal Average	Post Appeal Average
General Authority	25	$3,060	$2,600
BPC 4067	0	0	0
BPC 4126.5	0	0	0
BPC 4169	0	0	0
BPC 4317.5(a)	82	$17,195	$12,309
BPC 4317.5(b)	5	$56,000	$42,180

Franchise Tax Board Intercepts

DCA notifies the Board when the Franchise Tax Board (FTB) has intercepted California tax refunds to pay monies owed to the Board. (The FTB cannot intercept corporation or partnership funds but can intercept funds from sole ownership.) Over the past two years, the Board opened 31 intercept accounts and closed 18 accounts. The Board refers outstanding fines to the Franchise Tax Board (FTB).

DRAFT

Cost Recovery

California Business and Professions Code section 125.3 authorizes the recovery of investigation costs associated with the formal discipline of a license.

The Board's policy is to seek cost recovery in all cases where authorized. Reimbursement of Board costs is a standard term of probation listed in the Board's *Disciplinary Guidelines*. The Board seeks cost recovery in settlements as well as administrative decisions. In cases resulting in surrender or revocation of license, the Board seeks costs but does not generally require payment unless the licensee seeks relicensing or reinstatement of license. Costs awarded to the Board in probation cases typically are paid in installments and may not be fully collected until the end of the probation period - perhaps three to five years. It is important to note that administrative law judges do not always award costs to the Board.

The Board does not have the authority to seek cost recovery in a statement of issues case (where an applicant has appealed the denial of his or her application).
The Board has not used the Intercept Program to collect cost recovery. Rather, when a licensee on probation fails to submit cost recovery payments, generally the Board will pursue further administrative discipline for violation of probation. Where a license is revoked, typically costs are due upon reinstatement or reapplication.

Costs Awarded

	FY 24/25	FY 25/26	FY 26/27	FY 27/28
Revoked Licenses	$90,766	$24,808		
Surrendered Licenses	$571,176	$323,353		
Licenses on Probation	$548,002	$448,933		
Public Reproval	$272,893	$140,095		

Restitution

The Board has no legal authority to order restitution. Instead, the Board orders community service to compensate the public for violations of Pharmacy Law. As an example, the Board will include as part of a stipulated settlement a donation of either money or product to specified entities.

Table 11. Cost Recovery				
	FY 2024/25	**FY 2025/26**	**FY 2026/27**	**FY 2027/28**
Total Enforcement Expenditures	$3,633,500	$3,117,500		
Potential Cases for Recovery *	171	200		
Cases Recovery Ordered	139	81		
Amount of Cost Recovery Ordered	$1,500,344	$942,388		
Amount Collected	$953,691	$856,223		

*Cases in which disciplinary action has been taken based on violation of the license practice act.

Table 11a. Administrative Fines				
	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Amount Ordered	$100,000	$270,000		
Amount Collected	$100,000	$270,000		

The Board has no legal authority to order restitution. Instead, the Board orders community service to compensate the public for violations of Pharmacy Law.

Table 12. Restitution				
	FY 2024/25	FY 2025/26	FY 2026/27	FY 2027/28
Amount Ordered	n/a	n/a	n/a	n/a
Amount Collected		n/a	n//a	n/a

Section 6 – Public Information Policies

Internet Use and Meeting Materials

The Board uses the internet as its primary communication channel with the public. Electronic communication is the fastest way to disseminate important information on policy, regulatory, enforcement and consumer matters to patients, licensees and stakeholders.

All announcements, activities, documents and public records of importance to consumers and licensees – including meetings, rulemakings, new laws and regulations, drug recalls, licensure forms, reports and publications, and enforcement actions – are posted on the Board's website, www.pharmacy.ca.gov. In addition, notices with links to important information are emailed via seven separate listservs to over 135,000 individuals and organizations who have signed up to receive "subscriber alerts" from the Board. Board licensees are required by law to enroll in the Board's listservs.

The Board posts extensive meeting materials – including agendas, background information, action items and minutes – on a dedicated section for Board and committee meetings. Agendas are posted at least 10 days before meetings, and materials typically are posted five days before meetings. Within two days after meetings, the Board posts a list of action items from the meeting online and releases the information to the public via subscriber alerts.

Draft minutes are included in the meeting materials for the subsequent quarterly Board meeting, and final meeting minutes are posted online after they have been reviewed and approved at a Board meeting. The same timetable applies to materials for committee meetings.

Meeting materials remain on Board meetings page for several years, currently from April 2021 to present. In addition to posting comprehensive meeting materials online, the Board releases a monthly news roundup via subscriber alerts in an effort to keep consumers, licensees, and stakeholders informed about important activities and events.

Livestream

Board and Committee meetings (except teleconference meetings) are generally webcast live by the Department of Consumer Affairs. Webcast recordings are posted online on DCA's YouTube page; links to the recordings are posted on the Board's meeting page.

In addition to livestreaming meetings, the Board provides an opportunity for the public to participate in meetings via Webex. The Board is grateful for the support offered by the Department of Consumer Affairs that provide meeting moderators during these meetings. The Board values meetings convened by Webex as another important access point for interested parties to engage with the Board.

Meeting Schedule

The Board schedules two-day meetings each quarter and one-day meetings in various months. The Board approves an annual calendar typically in July for meetings throughout the following calendar year, and the schedule is posted upon approval. Committees typically meet once per quarter on dates approved by the committee chairperson and immediately posted online.

Occasionally, additional Board or committee meetings are scheduled respond to urgent matters. These meeting dates are posted online as soon as they are established, and alerts are emailed immediately to listserv subscribers.

Complaint Disclosure Policy and Posting of Enforcement Actions

The Board's complaint disclosure policy is consistent with DCA's Recommended Minimum Standards for Consumer Complaint Disclosure.

In addition, the Board posts accusations and disciplinary actions consistent with DCA's Web Site Posting of Accusations and Disciplinary Actions (May 21, 2010). An "Enforcement Actions" link in the "Quick Hits" column on the homepage leads to additional webpages that list by month each pending accusation, disciplinary action, and immediate protection order against licensees. Each case identifies licensees by name and number, enabling consumers to search online and find all the public documents available in the case. Lesser administrative actions – including citations, fines, and letters of admonishment – are not posted online. However, the information is public and available from the Board upon written request consistent with the Board's records retention schedule.

The website also includes explanatory information about public disclosure of disciplinary records, the Board's public disclosure policy, and disciplinary terminology. Public Information about Licensees

Public Information about Licensees

The Board provides key information online to enable the public to quickly search and verify the status of a license and any disciplinary action against a licensee. The Board's website includes quick access to the "Verify a License" link on its home page as part of the main

DRAFT

banner and also advertises this search option as one of its popular pages and under its "Information for Consumers".

Website visitors can perform a license search and find the following information about pharmacists, pharmacy technicians, pharmacist interns, and designated representatives:

- Licensee name.
- License type.
- License number.
- License status.
- License issue date.
- License expiration date.

In the interest of licensee safety, the Board removed addresses of record for individual licensees. However, addresses of record are public information that remain available by contacting the Board.

The same license information is provided for licensed sites, such as pharmacies, clinics, hospitals, and other locations. Site licenses also include links to the license of any individual required to oversee the site. (For example, pharmacies must have a designated pharmacist-in-charge.)

Each license record also discloses any formal discipline against the licensee, along with a link to public documents in the case. Information about lesser administrative actions – including citations, fines, and letters of admonishment – are not linked to licensees but is available by contacting the Board.

Consumer and Licensee Outreach

As a consumer protection agency, the Board relies on a variety of important communication tools to reach and educate the public. The CA Web Standards provides an online resource for state agencies to support implementation of the new standards. The Board's website was updated in June 2024 to make it more easy to navigate and includes new features including a calendar of meeting dates.

The Board's website remains the primary channel for mass communication. The Board's landing page includes a homepage section, "Information for Consumers," to highlight news, brochures and other useful information for consumers in an easy-to-find location as well as the Board's "verify a license" search.

In addition to its website, the Board maintains an X (formerly known as Twitter) social media account to reach individuals who receive information and communicate on mobile phones. To keep the public informed about important activities and events, the Board created a subscriber alert listserv to disseminate general news and information to consumers, news media, stakeholders and other non-licensee audiences.

The Board developed consumer education and license education campaigns and partners with the DCA to expand its reach. As an example, the Board developed a campaign

DRAFT

encouraging consumers to speak to their pharmacist and to educate the public that pharmacists are healthcare providers who are easily accessible and at no cost. The "Talk to the Expert" campaign included a QR code that let the consumer know that language translation services are available at no cost and additional steps a consumer can take to prevent medication errors. Five graphics were designed and were used in this campaign. This campaign is also on the Board's website.

The Board recognizes that consumers may not actively seek out the Board to learn about their rights to protection and safety, the Board updated the required Notice to Consumers. The poster focuses on actions, and consumer can take, with their pharmacist, to reduce medication errors while also including all mandatory notice requirements in the law. The notice includes a "Know Your Rights" section that summarizes California law to empower the consumer of their rights to receive medication legally prescribed to them.

Further, as issues emerge, the Board undertakes development of consumer education materials, including development of policy statements. The Board has a number of policy statements released intended to convey the Board's position on matters, including practice related items that are in a period of transition. For example, over the past two fiscal years the Board has released multiple policy statements including the Role of the Pharmacist-in-Charge, Standard of Care practice Models, Pharmacy Intern Hours Earned Outside of Formal Experiential Training, and Nonresident Pharmacies.

The Board continues its popular Ask an Inspector information program four days a week. Board inspectors are available four hours a day Monday through Thursday to receive phone calls and answer questions about pharmacy law and regulations from consumers, licensees, government agencies, and other stakeholders. In addition, inspectors research and respond in person to questions submitted by email.

Besides informing and educating consumers, the Board has expanded its professional outreach and continuing education programs (CE) for licensees. The Board continues to sponsor free full-day CE forums for pharmacists throughout California covering a range of topics including prescription drug abuse prevention, drug diversion trends, pharmacy law changes, and information on CURES. This training program continues to evolve and new modules added, including the recent edition of a presentation on the issue of stigma. Following this training, individuals that complete post training activities are awarded six hours of continuing education. Between March 2024 and September 2026, 74,907 individuals have completed this training program.

The Board has educational webinars that cover topics including Assembly Bill 1503, Removing Barriers and Improving Patient Safety, How to Prepare for a Board Inspection, Ethics, Corresponding Responsibility, Pharmacist-in-Charge, Overview and Responsibilities, and Opioid Antagonists for the Prevention of Opioid Overdose. Additionally, on an annual basis the Board updates its webinar on pharmacy law. These trainings are available through

the Board's learning management system, *PharmEd*, where pharmacists can complete the course and earn CE credit at their convenience.

The Board publishes fact sheets and brochures as well, including for example on how to prepare for a board inspection as well as information on corresponding responsibility considerations for dispensing buprenorphine.

The Board has also undertaken development of Frequently Asked Questions in a number of areas including as examples:

1. Ask an Inspector
2. Automated Drug Delivery Systems (ADDS)
3. Compounding Regulations
4. Continuing Education (CE)
5. Digital Records
6. Inventory Reconciliation Regulations
7. Medication Error Reporting
8. Minimum Staffing Provisions
9. Mobile Units
10. Technician Duties

These FAQs are living documents updated when necessary to incorporate additional items based on subsequent changes to provisions of pharmacy law and its regulations or in response to additional comments received.

Section 6 – Online Practice Issues

There are two primary categories of online practice within the Board's jurisdiction that are of concern to the Board. The first activity occurs when patients buy prescription drugs from unlicensed sellers. The second is the increased use of telehealth platforms and other online platforms that steer patients to specific pharmacies or collect protected health information.

Patients Buying Drugs Online

As the cost of prescription drugs continues to rise, it is not uncommon for consumers to look for cheaper medications online. In addition, unlicensed and unregulated entities often advertise cheaper drugs in unsolicited emails. On October 2, 2024, the Centers for Disease Control and Prevention (CDC) released a statement, "Potential public health risk among individuals ordering counterfeit prescription medications from online pharmacies." As part of its release the CDC referenced an indictment issued by the U.S. Department of Justice, against individuals running illegal online pharmacies. This CDC information also referenced findings by the National Association of Boards of Pharmacy (NABP) indicating that it had identified more than 40,000 websites that fail to comply with its patient safety and pharmacy practice standards.

Further in September 2023, ASOP Global Foundation released its findings based on a survey commissioned to survey Americans about their perceptions and use of online

pharmacies. The results reveal that more Americans are buying prescription medications online and included some alarming information, "24% of Americans with prior experience using online pharmacies, report having previously been exposed to harmful, counterfeit, or substandard medication received from an online pharmacy, a 7-percent increase from 2021."

Investigations into online pharmacies create unique challenges for the Board as online operators of unlicensed pharmacies easily hide the location of their facility as well as their ownership. Identifying website operators is difficult and may involve individuals doing business outside the United States, where the Board has no authority to enforce sanctions. The NABP investigation into foreign drug sellers masquerading as Canadian online pharmacies revealed that the medications dispensed were neither approved by the FDA or Health Canada.

This is not a new issue for the Board, yet regrettably the investigative tools available to the Board are insufficient to curb the increased unlicensed practice. Although the Board has cease and desist authority for unlicensed activity. Regrettably, the issuance of such an order does not stop the practice. The Board may issue a cease-and-desist order; however, while an operator may stop the specific activity identified in the order, they often reappear under a new website and continue to sell drugs illegally. Online pharmacy websites frequently emerge, shut down, and re-establish themselves, making enforcement particularly challenging. As a result, the Board is often unable to fully halt these unlawful practices.

The Board will continue to investigate these cases. However, because this issue frequently falls outside the Board's direct authority and jurisdiction, the Board will also continue to refer such complaints to the National Association of Boards of Pharmacy (NABP) and other appropriate agencies for further investigation.

Consumer education about the risks of purchasing from unlicensed pharmacy websites is essential. The Board includes a link to an educational resource developed by the NABP.

Telehealth Platforms

As indicated in the New Issues section of this report, the Board is concerned with an increase in the number of telehealth platforms that appear to steer patients to specific pharmacies as a condition of receiving medical care. In some instances, it appears that patients are using a telehealth platform that connects the patient with a medical provider authorized to prescribe medications. The patient is subsequently prescribed a medication to a specific pharmacy affiliated with the telehealth platform. It appears that in some instances the telehealth platform places conditions on the patient, including restricting the patient's choice for a pharmacy.

In addition, the Board sees an emerging trend that appears to be driven by application developers seeking to assist patients in managing their prescription information by the collection of protected health information stored within the application that may subsequently be used for other purposes including marketing specific products to these patients based on the information stored. In other instances, the individual's credit card is on

file their prescriptions are automatically refilled without authorization. This is another area where the Board's current investigative and enforcement tools are not sufficient to curb the practice.

Section 7 – Workforce Development and Job Creation

Pharmacists are highly trained professionals that in many respects are underutilized. Policy makers and regulators alike have recognized this and sought legislative changes to create additional patient care opportunities consistent with a pharmacist education and training. According to recent information published by the California Health Care Foundation, about 11.4 million Californian's live in a federally designated Primary Care Health Professional Shortage Area, and two-thirds of them are Black, Latino/x, or American Indian. As pharmacy business models evolve and new dispensing models take advantage of technology to fill prescriptions, opportunities for pharmacist to engage in more clinical services continue to expand.

During its last sunset review, the Board evaluated opportunities to expand pharmacist services and transition pharmacist practice to a more robust standard of care (SOC) practice model for specified services. With this change, prescriptive requirements were removed in favor of the SOC practice model. The Board notes that an SOC practice model already exists in pharmacist practice where pharmacists exercise independent clinical judgment to take care of their patients. To facilitate this transition to a more robust SOC practice model, the statute established a definition, "accepted standard of care" is the degree of care a prudent and reasonable pharmacist licensed pursuant to the Pharmacy Law, with similar education, training, experience, resources, and setting, would exercise in a similar situation." (BPC §4051(a))

Through the Board's prior sunset, pharmacists are now authorized to provide specified services and activities consistent with the accepted standard of care, including when authorizing the initiation of a prescription. This includes:

1. Furnish epinephrine
2. Furnish FDA-approved or authorized medications for preventative health care services that do not require a diagnosis, including the following:
   a. Emergency contraception
   b. Contraception
   c. Smoking cessation
   d. Travel medications
   e. Anti-viral or anti-infective medications.
3. Order and interpret tests.
4. Furnish medication used to reverse opioid overdose and medication used to treat substance use disorder (e.g. Naloxone).
5. Complete missing information on a prescription for a noncontrolled medication if there is evidence to support the change.
6. Initiate and administer immunizations for persons three years of age and older.

DRAFT

Another aspect of workforce development undertaken by the Board is the implementation of programs to educate licensees about pharmacist practice and prevent violations. Over the past several years the Board has dedicated significant time and effort to this education. The Board uses its newsletter to discuss changes in pharmacy law, areas of concerns, and trends in violations. The Board provides the following training opportunities for licensees:

- A six-hour training covering corresponding responsibility, pharmacy security and drug loss prevention, pharmacy law, and how to prepare for a Board inspection.
- CE webinars covering pharmacy law and ethics, Pharmacist-in-Charge: Overview and Responsibilities.

Impact of Licensing Delays

The Board understands its role in helping businesses and individuals enter the marketplace and strives to make licensing decisions quickly and efficiently.

Temporary license applications are prioritized for processing because applicants report a need to serve their patients; however, this delays processing for other types of licenses. Further, because temporary licenses expire sooner, a second pressure point occurs when staff is redirected again as the expiration date nears. The Board seeks to manage these priorities to ensure continuity of patient care and strives to provide education to applicants on common deficiencies as a means to assist applicants with submitting complete applications.

Processing times for various licensing programs vary. As the data reveals in Section 3, the majority of complete applications received are processed within 30 days for all individual license programs.

The Board notes that its reliance on a legacy computer system for management of its application and licensing data creates barriers to achieving efficiencies in the application process. Ultimately, the long-term solution will be an integrated computer system that will facilitate a more streamlined application process and improved user interface. As detailed in this report, the Board is engaging in Business Modernization activities, a process intended to assess current operations and identify ways to achieve efficiency by changing processes, replacing legacy computer systems, or doing both. As this process continues, the Board will evaluate opportunities to implement improvements that do not require a new computer system.

Informing Potential Licensees of the Licensing Requirements and Licensing Process

There are currently 14 approved pharmacy schools. The Board works with faculty at the schools to streamline the application process and participates in biannual meetings with the deans. In addition, the Board collaborates with schools to expedite processing of pharmacist applicants entering residencies. This helps ensure an applicant is licensed in time to complete residency programs consistent with accreditation guidelines.

DRAFT

The Board provides presentations at pharmacy schools providing education on application requirements and licensure process.

Barriers to Licensure and/or Employment

The Board is not aware of any systemic barriers to licensure. The Board notes that the U.S. Bureau of Labor Statistics estimates that employment of pharmacists is projected to grow five percent from 2023 to 2033 with about14,2000 openings for pharmacists are projected each year.

The Board is concerned that the cost of pharmacy school may be a deterrent to some individuals selecting the pharmacy profession.

Workforce Development Data

The Board does not maintain workforce development data but does promote the workforce survey conducted by the California Department of Health Care Access and Information.

Workforce Shortages

The Board is not aware of any workforce shortages. According to the Pharmacy Workforce Center, in the fourth quarter of 2025, California had 2,508 job postings for pharmacists and at any given time there is an average of 3,000 job postings for pharmacy technicians.

Successful Training Programs

The Board reports the pass rates of the pharmacist licensure examination, including the rates for each pharmacy school. This information is provided in Board meeting and posted on the Board's website.

Eliminating Inequities

The Board seeks to address inequities with a focus on diversity, equity and inclusion (DEI) initiatives. Members of the Board come diverse backgrounds, with two of the Board's current leaders being members of the LGBTQ community. The Board's strategic plan places emphasis on policies and law that are inclusive for all and the Board's administrative manual underscores its commitment to the tenets of DEI. Board staff have undertaken a number of training course including addressing unconscious bias and DEI.

Pharmacy law requires mandatory cultural competency continuing education for pharmacists and pharmacy technicians. The Board's Notice to Consumers (Notice) poster includes a QR code on the notice, providing access to the Notice in 16 additional languages. Further, pharmacies are required to provide translation services under specified conditions and consumers have access to language lines in pharmacies.

DRAFT

Section 8 – New Issues

Future Information Technology Needs

The Board continues its business modernization activities through the Department of Technology's Project Approval Lifecycle (PAL). The project is currently progressing through the required PAL stages, which include defining business needs, evaluating solution options, and preparing for system development and implementation. Current efforts focus on defining business needs, assessing solution options, and preparing for future system development.

Online Applications and Payment Capability as Workaround Systems

In partnership with DCA, the Board has implemented online renewal payments for 10 of its licensing programs including online renewals for pharmacists, pharmacy technicians, pharmacies and hospitals. The Board is also leveraging DCA's platform for online application submission for military spouses and partners seeking temporary licensure. To further leverage this online functionality, the Board is encouraging all individual licensees to renewal their licenses online. The online process is more streamlined and allows for renewal to occur in about 2 days. This stands in contrast to the manual process that can take two weeks and relies heavily on factors outside of the licensee's control, including mail service and staffing resources within the Board and the DCA. Additionally, Board staff are working to increase the number of licensing programs eligible for online renewals.

Section 9 – Board Action and Response to Prior Sunset Issues

Assembly Bill (AB) 1503 is the Board's sunset measure. The measure extends the operations of the Board until January 1, 2030. The measure also includes several policy issues raised by the Board in its 2025 Sunset Oversight Review Report. The measure was approved by Governor Newsom on October 1, 2025.

Given the comprehensive nature of the measure and the significant activities required for implementation, the oversight of such activities was referred to the Licensing Committee.

The current status of AB 1503 implementation is summarized below. The Board approved a recommendation to award 1 hour of CE to complete the Board's online webinar on AB 1503. Since that time, the webinar has been added to the Board's PharmEd learning management system, and 773 pharmacists have completed the training.

New BPC Section 4001.5, Related to the Pharmacy Technician Advisory Committee (PTAC)
Summary: This new section requires the Board to establish an advisory committee to advise and make recommendations to the Board on matters related to pharmacy technicians. The committee shall consist of four licensed pharmacy technicians representing a range of practice settings; two licensed pharmacists, one of whom shall be a member of the Board; and one public member.

DRAFT

Implementation Status: The Board finalized the appointment process, duration of appointment, and minimum qualifications for individuals interested in serving on the PTAC. The Board Member Procedure Manual has been updated to reflect the addition of the PTAC. Dr. Satinder Sandhu was appointed by President Oh to serve as the Board member on the PTAC. The online application portal was implemented. As of the end of October 2026, 84 applications have been received.

Amended BPC Sections 4016.5, 4210, and 4233, Related to Advanced Pharmacist Practitioners (Formerly Known as Advanced Practice Pharmacists)

Summary: Renames the title "Advanced Practice Pharmacist" to "Advanced Pharmacist Practitioner."

Implementation Status: Board staff have prepared the Section 100 regulation changes for the following sections of title 16, California Code of Regulations (CCR): 1702, 1702.1, 1706.6, 1730, 1730.1, 1730.2, and 1749. The Application and Instructions for Advanced Pharmacist Practitioner Licensure, the Duplicate/Replacement License Request, the online PDF renewal application, and the CE FAQs have been updated, and the new versions are on the Board's website. The technical changes to the Board's IT systems have been completed. The prepared rulemaking documents are undergoing pre-notice review by the Department of Consumer Affairs.

Amended BPC Section 4036, Pharmacist Defined

Summary: Updates the definition of "pharmacist" to provide that the holder of an unexpired and active pharmacist license issued by the Board is entitled to practice pharmacy as defined by Chapter 9 of Division 2 of the BPC, within or outside of a licensed pharmacy.

Implementation Status: The Board approved the initiation of a rulemaking to add section 1717.11, Remote Processing of Prescriptions, to title 16 of the CCR and the proposed regulatory text was released for a 45-day comment period. Members considered comments received during the 45-day comment period and voted to further modify the proposed regulation text based on the comments received. The revised text went out for a 15-day comment period after which the Board adopted the proposed regulation text. Staff prepared the post-adoption regulation materials, which are currently under review with Agency.

New BPC Sections 4040.6 and 4102, Related to Self-Assessment Process

Summary: Establishes the self-assessment process in statute.

Implementation Status: The updated Community Pharmacy Self-Assessment/Hospital Outpatient Self-Assessment was approved by the Board and posted on the Board's website. The Board approved the updated self-assessment forms for Wholesaler/Third Party Logistics Providers, Surgical Clinics, and Hospital Pharmacies, Automated Drug Delivery Systems and Compounding and a new self-assessment form for Outsourcing Facilities. The Board was advised by the Office of Administrative Law (OAL) that it could not pursue the streamlined Section 100 regulation changes for the following sections, title 16 of the CCR: 1715, 1715.1,

1735.1, 1736.1, and 1784. The Board voted to initiate a regular rulemaking to repeal regulations that are no longer required given the statutory changes made in AB 1503. The rulemaking was submitted to OAL and will be noticed on October 23, 2026.

Amended BPC Sections 4051 and 4052, Related to Standard of Care

Summary: Defines "accepted standard of care" and transitions some provisions for pharmacist-provided health care services to a standard of care practice model, including in the following areas:

1. Furnish epinephrine
2. Furnish FDA-approved or authorized medications as part of preventative health care services that do not require a diagnosis, including the following:
   a. Emergency contraception
   b. Contraception
   c. Smoking cessation
   d. Travel medications
   e. Anti-viral or anti-infective medications
3. Order and interpret tests
4. Furnish medication used to reverse opioid overdose and medication used to treat substance use disorder (e.g. Naloxone)
5. Complete missing information on a prescription for a noncontrolled medication if there is evidence to support the change
6. Initiate and administer immunizations for persons three years of age and older

The law also provides that a pharmacist should not provide a service or function if the pharmacist has made a professional determination that (1) they lack sufficient education, training, or expertise, or access to sufficient patient medical information, to perform the service or function properly or safely; (2) performing or providing the service or function would place a patient at risk; or (3) pharmacist staffing at the pharmacy is insufficient to facilitate comprehensive patient care. Provisions also establish a notification requirement to a patient's primary care provider, as specified.

As part of the transition to a standard of care practice model for certain pharmacist-provided health care services, some provisions of law that established prescriptive requirements and/or required pharmacists to follow standardized procedures and protocols have been repealed, for example, former BPC sections 4052.01, 4052.02, 4052.03, 4052.3, 4052.8, and 4052.9.

Implementation Status: The Board removed the current online training regarding HIV PEP and PrEP, prepared the Section 100 regulation changes and approved the policy statement related to the standard of care practice model which has been posted on the Board's website, and updated the Board Member Procedure Manual to reflect the addition of the policy statement have been made. As directed by OAL the Board could not pursue the streamlined Section 100 process to repeal regulations affected by the standard of care transition, therefore, the Board voted to initiate a regular rulemaking to repeal regulations that are no longer required given the statutory changes made in AB 1503, which include title

DRAFT

16 of the CCR: 1732.5, 1746, 1746.1, 1746.2, 1746.3, 1746.4, 1746.5, and 1747. The rulemaking was submitted to OAL and will be noticed on October 23, 2026.

Amended BPC Sections 4081 and 4105, Related to Pharmacy Records
Summary: Updates pharmacy records requirements to specify that policies and procedures related to pharmacy personnel and pharmacy operations must also be maintained. Allows all records to be maintained in digitized format subject to specified conditions.

Implementation Status: The Board has approved FAQs regarding digitizing records.

Amended BPC Section 4111, Related to Ownership Prohibitions
Summary: Updates ownership prohibition to allow for ownership of a pharmacy by a person with whom the person shares a community or other financial interest under specified conditions.

Implementation Status: The pharmacy license applications and instructions have been updated.

Amended BPC Sections 4112, 4113, and 4113.1, Related to Nonresident Pharmacies
Summary: Effective July 1, 2026, the requirements for a nonresident pharmacy to include authority for the Board to inspect a nonresident pharmacy and assess a reasonable fee to cover the Board's costs. Further, effective July 1, 2026, requires a nonresident pharmacy to designate a California-licensed pharmacist to serve as the pharmacist-in-charge (PIC). In addition, updates the medication error reporting requirements for nonresident pharmacies to clarify that only medication errors related to prescriptions dispensed to California residents must be reported.

Implementation Status: The updated FAQs related to medication error reporting and the nonresident pharmacy application and instructions have been updated and posted on the Board's website. The Board released subscriber alerts describing all of the relevant changes impacting nonresident pharmacies; added two additional CPJE test administration dates to provide more opportunities for pharmacists seeking California licensure to serve as the PIC of a nonresident pharmacy; and provided email notification to nonresident pharmacies describing relevant changes. In addition, the Board's policy statement on the role of the PIC, which highlighted relevant changes related to PICs of nonresident pharmacies, was posted on the Board's website. The Board voted to approve a policy statement related to nonresident pharmacies. In addition to subscriber alerts and emails, staff released correspondence to all nonresident pharmacies that have not yet taken steps to comply with the new PIC requirements and directly contacted each facility via phone calls. As of October 12, 2026, 348 nonresident pharmacies have identified a California-licensed pharmacist to serve as the PIC. This represents approximately 64% of all nonresident pharmacies licensed in California. Board staff continue to focus on securing compliance through education.

DRAFT

Amended BPC Section 4113, Related to Pharmacist-in-charge, Staffing
Summary: Provides that the Pharmacist-in-Charge (PIC) shall (instead of may) make staffing decisions at the pharmacy. Requires the PIC to determine appropriate pharmacist to technician ratio, which may not exceed 1 pharmacist to 3 pharmacy technicians (1:3).

Implementation Status: The Board's policy statement related to the role of a PIC, the Board Member Procedure Manual to reflect the addition of the policy statement have been made and the updated FAQs related to PIC staffing authority have been posted on the Board's website. The Board's Pharmacist-in-Charge: Overview and Responsibilities Training webinar has been updated and made available in the Board's learning management system.

Amended BPC Section 4113.6, Related to Chain Community Pharmacy
Summary: Requires a chain community pharmacy to post, in a prominent place for pharmacy personnel, a notice that provides information on how to file a complaint with the Board.

Implementation Status: The sample notice developed by the Communication and Public Education Committee has been posted on the website.

Amended BPC Section 4115, Related to Pharmacy Technicians
Summary: Clarifies the authorized duties of a certified pharmacy technician, increases the pharmacist to pharmacy technician ratio, and establishes authority for pharmacy technicians to perform specified duties outside of a licensed pharmacy.

Implementation Status: The updated FAQs have been posted on the Board's website.

Amended BPC Section 4200.5, Related to Retired Pharmacist License
Summary: Establishes provisions for an individual to restore their retired pharmacist license under specified conditions.

Implementation Status: The retired pharmacist form has been updated to include provisions for restoration of a license.

New BPC Section 4317.6, Related to Mail Order Pharmacy
Summary: Establishes provisions to allow the Board to issue fines to mail order pharmacies for up to $100,000 under specified conditions.

Implementation Status: The citation and fine presentation was given to the Enforcement and Compounding Committee and since then the Board has not issued any fines under BPC 4317.6.

Amended BPC Section 4400, Related to Fees
Summary: Establishes authority for the Board to waive the application and renewal fee for a pharmacy providing in-person patient care services in a medically underserved area, as defined.

DRAFT

Implementation Status: There is currently one licensed pharmacy that meets the eligibility requirements for a fee waiver. The Board will continue to monitor implementation for at least another six months.

Section 10 – New Issues

A comprehensive review of these issues will be addressed by the Board in the final Sunset report to the legislature.

Section 11 – Attachments

Attachments will be provided in the final Sunset report to the legislature.

DRAFT